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ABSTRACT 
Special age groups (children, adolescents, older adults) have special characteristics 
when it comes to pain assessment, pain experience, and pain management. The first 
objectives of the current study were to examine pain coping in children and to 
identify factors related to pain in older adults, in order to improve the understanding 
of the pain experience in these special age groups. First, the factor structure of the 
Finnish translation of the Pain Coping Questionnaire (PCQ), the first validated pain 
coping measurement developed specifically for children, was determined and 
validated. Secondly, the pain intensity and interference as well as pain-related factors 
according to the SF-36 were examined among community-dwelling older adults. In 
addition, purchases of prescribed analgesics among older adults were considered in 
order to estimate the analgesic administration prevalence in the aging population. 
The main focus was in opioid purchases due to the known increase in opioid use 
among older adults. 
Exploratory factor analysis was used for the first-order and higher-order 
classification of 91 juvenile idiopathic arthritis patients and patients with chronic 
non-inflammatory musculoskeletal pain symptoms, aged 8–15. A total of 1,420 
randomly selected community-dwelling older adults self-reported SF-36 bodily pain 
(pain intensity and pain-related interference) during the previous month. Based on 
the pain reports, four pain groups were formed (group I [0–45, moderate to very 
severe pain intensity and interference], group II [47.5–70], group III [77.5–90], and 
group IV [100, no pain at all]). The relationship between questionnaire and clinical 
data in these groups was explored. Data regarding older adults’ analgesic purchases 
for six months prior to and six months after the self-report were retrieved from the 
Social Insurance Institution of Finland. Analgesic purchases were examined 
separately in three age groups (62–66, 72–76, and 82–86 years). Factors related to 
analgesic purchases were explored.  
With 38 items, the exploratory factor analysis of the PCQ provided a both 
culturally and statistically satisfactory structure of eight first-order factors 
(Internalizing/Catastrophizing [IC], Positive Self-Statements [PSS], Information 
Seeking [IS], Seeking Social Support [SSS], Cognitive Distraction [CD], Externalizing 
[EXT], Behavioural Distraction [BD], Problem Solving [PS]) and three higher-order 
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factors (Approach [APP], Emotion-Focused Avoidance [EFA], Distraction [DIS]) 
in the Finnish translation. Regarding older adults, the overall pain prevalence was 
78% (SF-36 bodily pain < 100); 17% had experienced both moderate to severe pain 
intensity and pain-related interference. The prevalence of cohabiting as well as 
socioeconomic status decreased, and obesity and morbidity increased with increasing 
SF-36 bodily pain. In total, 84% of the participants had purchased at least one 
prescribed analgesic over the period of one year; 77% had purchased non-steroidal 
anti-inflammatory drugs (NSAIDs), and 32% had purchased opioids. Of all 
examined factors, only morbidities were independently associated with analgesic 
purchases. Age did not make a marked difference in drug distribution or purchasing 
prevalence. Of the opioid purchasers, 16% had reported no pain of any intensity and 
30% no pain-related interference. Metabolic syndrome and morbidities were 
independently associated with opioid purchases among these participants.  
Children may lack understanding and the means to deal with ongoing unwanted 
physical and mental health conditions. A valid pain coping scale may enhance the 
distinguishing of vulnerable pain coping at the very early stage of pain becoming 
chronic. In older adults, a high prevalence of intense and interfering pain was 
reported. Multiple factors that were found to relate to pain are known to associate 
with social exclusion. Increasing efforts should be targeted towards identifying these 
factors in persons with pain. The use of NSAIDs and opioids emerged as being 
substantial in the older adult population. Careful deliberation in terms of 
contraindications and potential risks needs to be executed when prescribing NSAIDs 
and opioids to older adults, especially in older adults with a lower socio-economic 
status, obesity, and metabolic syndrome.   
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TIIVISTELMÄ 
Kivun arviointiin, kipukokemukseen ja kivun hoitoon liittyy erityispiirteitä ja 
haasteita erityisikäryhmissä (lapset, ikääntyneet). Tutkimuksen tavoitteena oli tutkia 
kipuun sopeutumista lapsilla ja nuorilla sekä löytää tekijöitä, jotka ovat yhteydessä 
koettuun kipuun ikääntyneillä. Tutkimuksen tavoite oli siten kehittää keinoja 
ymmärtää paremmin näiden erityisikäryhmien kipukokemusta. Tutkimuksessa 
määritettiin englannista suomeksi käännetyn kipusopeutumismittarin (PCQ) 
faktorirakenne, ja suomenkielinen PCQ validoitiin. PCQ on ensimmäinen 
nimenomaan lapsille kehitetty kipusopeutumismittari. Tutkimuksessa tarkasteltiin 
myös ikääntyneiden SF-36-mittarilla arvioitua kivun voimakkuutta ja haittaavuutta 
sekä näihin liittyviä tekijöitä. Lisäksi tarkasteltiin ikääntyneiden 
reseptikipulääkeostoja, jotta saataisiin enemmän tietoa ikääntyvän väestön 
kipulääkkeiden käytöstä sekä kipulääkeprofiilista. Päähuomio kohdennettiin 
opioidiostoihin, sillä opioidien käytön tiedetään lisääntyneen ikääntyneessä 
väestössä. 
Lastenreumaa sairastavien ja pitkittyneestä kivusta kärsivien lasten (N=91, ikä 8–
15 vuotta) kipuoireet jaoteltiin ensimmäisen ja korkeamman asteen luokkiin käyttäen 
eksploratiivista faktorianalyysiä. Satunnaisotannalla valikoidut, kotona asuvat 
ikääntyneet (N=1420) raportoivat SF-36-mittarilla kokemaansa ruumiillista kipua 
viimeisen kuukauden ajalta. Kipuraportoinnin perusteella tutkittavat jaettiin neljään 
kipuryhmään (ryhmä I [0–45, kohtalainen–erittäin kova kivun voimakkuus sekä 
kipuun liittyvä haitta], ryhmä II [47,5–70], ryhmä III [77,5–90], ryhmä [100, ei 
lainkaan kipua]). Ikääntyneiden raportoimia kyselytietoja sekä kliinistä aineistoa 
tarkasteltiin suhteessa kipuun. Ikääntyneiden reseptikipulääkeostot kuudelta 
kuukaudelta ennen kyselykaavakkeen täyttöä ja kuudelta kuukaudelta sen jälkeen 
kerättiin Kansaneläkelaitoksen reseptitietokeskuksesta. Kipulääkeostoja tarkasteltiin 
erikseen kolmessa ikäryhmässä (62–66-, 72–76- ja 82–86-vuotiaat). 
Kulttuurisesti ja tilastollisesti tyydyttävä suomenkielisen PCQ:n ensimmäisen ja 
korkeamman asteen faktorirakenne saavutettiin 38 muuttujalla. Ikääntyneistä 78 % 
raportoi kokeneensa kipua viimeisen kuukauden aikana (SF-36 kipu < 100); 17 % oli 
kokenut sekä kohtalaista tai erittäin kovaa kipua että kohtalaista tai erittäin 
voimakasta kipuun liittyvää haittaa. Ne henkilöt, jotka raportoivat eniten kipua, 
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asuivat useammin yksin, sijoittuivat matalampaan sosioekonomiseen luokkaan ja 
olivat useammin ylipainoisia sekä monisairaampia. Ikääntyneistä 84 % oli vuoden 
aikana noutanut apteekista jotakin reseptillä määrättyä kipulääkettä; 77 % oli 
noutanut tulehduskipulääkkeitä ja 32 % opioideja. Ainoastaan sairauksien määrä oli 
itsenäisesti yhteydessä kipulääkeostoihin. Eri ikäryhmien välillä ei löytynyt 
mainittavaa eroa kipulääkejakaumassa tai noutojen esiintyvyydessä. Metabolinen 
oireyhtymä ja yleinen sairastavuus olivat itsenäisesti yhteydessä opioidien käyttöön 
niillä henkilöillä, jotka olivat noutaneet reseptillä määrättyjä opioideja mutta eivät 
olleet raportoineet lainkaan kipua. 
Lapsilta voi puuttua keinoja käsitellä epämiellyttäviä fyysisiä ja psyykkisiä 
kokemuksia. Validi kipusopeutumismittari voi edistää heikon kivun käsittelykyvyn 
tunnistamista ennen kuin kipu kroonistuu. Merkittävä osa ikääntyneistä oli 
raportoinut kipua viimeksi kuluneen kuukauden aikana. Useiden tekijöiden, joiden 
todettiin olevan yhteydessä kipuun näillä henkilöillä, tiedetään olevan yhteydessä 
sosiaaliseen syrjäytymiseen. Huomiota tulee kiinnittää kyseisten tekijöiden varhaiseen 
tunnistamiseen kipua kokevilla henkilöillä. Tulehduskipulääkkeiden ja opioidien 
käyttö ikääntyneillä oli runsasta. Huolellista harkintaa tulee käyttää näiden lääkkeiden 
määräämisessä ikääntyneelle väestölle, ja vasta-aiheet ja mahdolliset riskit tulee 
tuntea. Erityishuomiota tulee kiinnittää niihin ikääntyviin henkilöihin, jotka 
sijoittuvat matalampaan sosioekonomiseen luokkaan, ovat ylipainoisia ja joilla on 
metabolinen oireyhtymä.   
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1 INTRODUCTION 
Pain is known to be a major factor affecting the quality of life in children and older 
adults (Varni et al. 1996b, Schanberg et al. 1996, Bernfort et al. 2015, Chen et al. 
2003, Lacey et al. 2014). Evaluating pain is known to be complex (Jensen et al. 1986, 
Breivik et al. 2008). Pain is always subjective and includes an emotional component 
(IASP 2018). Self-reporting has long been considered the most reliable method of 
measuring pain in children aged six years and older (Beltramini et al. 2017) and in 
older adults, also with possible cognitive impairments (Bicket and Mao 2015, Booker 
and Haedtke 2016, Hadjistavropoulos et al. 2010).  
Juvenile pain coping is a process under pediatricians’ increasing attention. The 
growing consensus supports the significance of pain coping in the understanding of 
prolonged pain in children (Reid et al. 1998, Gil et al. 1993, Claar et al. 2008). Coping 
signifies purposeful cognitive and behavioral efforts to deal with the negative impact 
of stress (Lazarus 1993). More precise knowledge about each individual’s pain coping 
style may enhance the optimization of treatment and also help professionals to 
predict psychological adjustment and pain levels (Bennett-Branson 1993, Gil et al. 
1993, Keefe et al. 1990, Olson et al. 1993). 
The Pain Coping Questionnaire (PCQ) is the first validated pain coping 
measurement developed specifically for children (Reid et al. 1998). It comprises pain 
coping strategies, indicating how often children would execute each strategy when 
in pain. In 1998, the 39 original PCQ items were grouped into eight conceptually 
derived first-order scales (Information Seeking, Problem Solving, Seeking Social 
Support, Positive Self-Statements, Behavioral Distraction, Cognitive Distraction, 
Externalizing, Internalizing/Catastrophizing) and three higher-order scales 
(Approach, Emotion-Focused Avoidance, Distraction) in an exploratory factor 
analysis. The PCQ has been translated into Finnish, but the translation has lacked a 
proper validation. To date, only Reid and colleagues had been able to confirm the 
higher-order exploratory factor structure of the PCQ. In pain treatment, besides pain 
intensity, it is important to distinguish the cognitive-emotional processed related to 
pain, as an understanding of these may lead to mechanisms of improvement 
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(Wicksell et al. 2011). A higher-order analysis would yield more information on the 
hierarchical structure of coping with pain. 
The number of studies regarding pain in older adults has multiplied during the 
last decade. However, the overall consensus highlights the under-assessment, under-
diagnosing, and under-treatment/mistreatment of persistent pain in older people 
(Gagliese and Melzack 1997, Tracy and Sean Morrison 2013, Veal et al. 2015, Nawai 
et al. 2017). It has been suggested that pain prevalence in older adults would be as 
high as 86% (Miranda et al. 2012) . Pain-related interference is an obvious problem 
in older age groups (Blyth et al. 2001, Gagliese and Melzack 1997).  
The association between chronic pain and sociodemographic factors has been 
presented in adults aged 25 years and older (Elliott et al. 1999). Sadness and 
loneliness have been reported to be more frequent among older adults with pain 
(Rapo-Pylkko et al. 2016, Jaremka et al. 2014). Furthermore, pain is known to 
associate with depression and obesity in older people (Han et al. 2016, Reid et al. 
2003, McCarthy et al. 2009).  
According to a large literature review regarding pain management in older adults 
(92 studies from 1990 to 2014), paracetamol was considered to be the first-line 
therapy (Makris et al. 2014). NSAIDs may be used if contraindications are not 
present (Makris et al. 2014, Abdulla et al. 2013). Opioid administration may be 
considered with both (moderate to severe) cancer and non-cancer pain, but only 
after a precise individual deliberation and with careful monitoring (Abdulla et al. 
2013, Huang and Mallet 2013). Neuropathic drugs should be considered for 
neuropathic pain (Abdulla et al. 2013), the prevalence of which is known to increase 
with advancing age (Schmader et al. 2010). The treatment strategy should be based 
on a proper assessment of the quality of pain and the patient’s individual needs 
(Spahr et al. 2017, Torrance et al. 2006). Large studies evaluating analgesic use in the 
general aged population are scarce, and the study settings are subject to wide variety. 
It remains unclear how large a proportion of the older population actually uses pain 
medication, whether the use is regular or on an as-needed basis, and whether the 
medication consists of NSAIDs, paracetamol, neuropathic drugs, or opioids (Rapo-
Pylkko et al. 2016, Gnjidic et al. 2014). 
Pain management could be further improved with a better understanding of the 
pain experience and a better assessment of multiple factors that may affect and relate 
to pain. Firstly, the objective herein was to determine the first- and the higher-order 
factor structure and to validate the Finnish version of the PCQ, thus providing tools 
for a better understanding of children and adolescents in pain. Secondly, the priority 
was to explore pain-related factors in the older adult population. Better knowledge 
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about the factors related to pain would facilitate the distinguishing of the risk group 
in which pain may become chronic, in addition to improving pain prevention. 
Thirdly, the analgesic purchases by older adults were considered in order to clarify 
the analgesic administration profile among older community-dwelling citizens. 
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2 REVIEW OF THE LITERATURE 
2.1 Definition of pain 
2.1.1 The definition and experience of pain 
According to definition by The International Association for the Study of Pain 
(IASP), pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage (IASP 2018, 
IASP 1994). Thus, pain is always subjective and includes an emotional component 
(IASP 2018, Wade et al. 1990). Reported pain should be regarded as pain even in the 
absence of tissue damage (IASP 2018). 
Based on a classification by duration, pain may be regarded as acute or chronic. 
Although chronic pain has classically been defined as pain which persists past the 
normal time of healing (Merskey 1994) and lacks the warning function of 
physiological nociception (Treede et al. 2015), a significant difference between acute 
and chronic pain does not originate from the concept of time alone. Acute pain is 
commonly a symptom of a disease or injury, while chronic pain is an individual 
condition (although often originating from an underlying condition) (Bicket and 
Mao 2015) and should be treated as one (Niv and Devor 2004, Raffaeli and Arnaudo 
2017). Usually, pain may be regarded as chronic when it recurs for over 3–6 months 
(Treede et al. 2015). 
The pain experience does not equate pain intensity. The experience of pain is 
always subjective and consists of sensory, cognitive-evaluative, and affective-
motivational dimensions (Wade et al. 1990, Price et al. 1987). Pain interference is an 
important element that is not always parallel to either pain intensity or tissue damage 
but is in a key role in terms of the effect on the individual’s quality of life. Pain 
interference refers to the degree to which pain interferes with an individual’s 
physical, mental, and social activities (Amtmann et al. 2010). Negative emotions—
for example, anger, frustration, anxiety, and depression—are important contributors 
of the overall unpleasantness of chronic pain (Wade et al. 1990). 
 21 
2.1.2 Types of pain 
Pain has originally been characterized as nociceptive or neuropathic; however, they 
sometimes occur together and are referred to as multi-mechanistic pain (Pergolizzi 
et al. 2017). Nociceptive pain arises from a peripheral noxious stimulus interpreted 
by the brain (Pergolizzi et al. 2017). Neuropathic pain has classically been defined as 
pain with a demonstrable lesion or disease of the somatosensory nervous system 
(IASP 2018). However, according to a more liberal approach, it may also occur 
without an obvious injury but arise from a dysfunction or inappropriate signal 
transmission (Fornasari 2012). Later on, it has been suggested to be useful to further 
classify neuropathic pain into possible, probable, and definite neuropathic pain 
(Finnerup et al. 2016).   
However, the characterization of pain—especially of chronic pain—is rarely this 
simple. As a result of multi-morbidity, chronic geriatric pain seldom arises from one 
etiology (Thakral et al. 2016). For example, due to complexity, the up-to-date 
classification of chronic pain for the ICD-11 divided chronic pain into seven groups 
(primary pain, cancer pain, posttraumatic and postsurgical pain, neuropathic pain, 
headache and orofacial pain, visceral pain, and musculoskeletal pain) in order to be 
able to execute the classification combining the etiology, type, and location of pain 
(Treede et al. 2015). However, as far as possible, the type of pain should be carefully 
identified in order to achieve optimal treatment regimens and better outcomes 
(Spahr et al. 2017, Torrance et al. 2006). 
2.2 Prevalence of pain 
Children who are predisposed to persistent pain are severely impaired in their daily 
activities, such as attending school, and may suffer from severe emotional distress 
(Coffelt et al. 2013, Zernikow et al. 2012). According to a Norwegian study 
(N=1,238, school children aged 8–18), the prevalence of pain within the previous 3 
months was 60% (Haraldstad et al. 2011). Therein, pain-related sleep disturbances, 
absences from school, and restricted social activities were reported (Haraldstad et al. 
2011). Estimates of recurrent and chronic pain in children suggest a prevalence of 
15%–25% (Mazur et al. 2013). In 2011, a large systematic review reported the 
prevalence of chronic and recurrent pain in children and adolescents as follows: 8%–
83% for headache, 4%–53% for abdominal pain, 14%–24% for back pain, 4%–40% 
for musculoskeletal pain, 4%–49% for multiple pains, and 5%–88% for other types 
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of pain (King et al. 2011). In a large Finnish study examining musculoskeletal pain 
in school children, 32% of the children reported having pain at least once a week, 
and half of these children still had pain at the 1-year follow-up (Mikkelsson et al. 
1997). Therein, 43% of the children with widespread pain reported absences from 
school due to pain (Mikkelsson et al. 1997). 
The ageing of the population is one of the most pervasive phenomena globally. 
Chronic pain has been considered to be one of the leading conditions in later life in 
terms of commonness and economic burden (Bicket and Mao 2015). Study results 
regarding the prevalence of pain among older adults show a wide variety (prevalence 
of 14%–86%) (Abdulla et al. 2013, Miranda et al. 2012, Barkin et al. 2005, Blyth et 
al. 2001, Bicket and Mao 2015, Brattberg et al. 1996, Larsson et al. 2017, Patel et al. 
2013, Satghare et al. 2016), but so do the study settings. Additionally, the prevalence 
of pain among hospitalized seniors has been reported to be high and frequently 
undertreated (Gianni et al. 2010). Pain-related interference has been reported to be 
significant (Blyth et al. 2001, Gagliese and Melzack 1997). Examples of systematic 
reviews exploring population-based settings and presenting the prevalence of pain 
among older people are presented in Table 1. They show that pain prevalence varies 
greatly depending on population characteristics, study settings, and various 
assessment methods. 
In 2015, Karttunen and colleagues presented the results of their study examining 
the persistence of chronic non-cancer musculoskeletal pain among Finnish 
community-dwelling older adults aged 76 years and older (Karttunen et al. 2015). At 
baseline, half of the participants reported chronic pain (Karttunen et al. 2015). Three 
out of four of these individuals continued to experience pain over the follow-up and, 
thus, objectively had persistent pain (Karttunen et al. 2015). 
Chronic pain comprises an enormous economic burden to society. In 2010, the 
total costs associated with chronic pain among the adult population in the USA were 
estimated to be $560–635 billion (Gaskin and Richard 2012). This amount comprises 
both medical treatment and loss of worker productivity (Gaskin and Richard 2012). 
The direct and indirect costs of patients with a diagnosis related to chronic pain have 
been estimated to account for one tenth of the Swedish gross domestic product (32 
billion EUR/year) (Gustavsson et al. 2012). The heaviest burden, however, is the 
one that is carried by the individual and his or her family members. Pain has been 
cited as one of the most disabling conditions for older people (Ettinger et al. 1994, 
Leveille et al. 2002).  
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2.3 Pain assessment 
2.3.1 Pain assessment in children 
According to the literature, the lack of proper pain assessment tools results in the 
underestimation and under-treatment of pain in children (Manworren and Stinson 
2016, Beltramini et al. 2017). Pain-causing conditions in childhood and adolescence 
vary significantly in nature. Age and the stage of cognitive development constitute 
challenges, and not all age groups should be approached similarly (Beltramini et al. 
2017, Manworren and Stinson 2016). Children in the non-verbal stage of 
development or with cognitive impairments are at an increased risk of 
underestimated and under-treated pain, but they are also more vulnerable to pain 
(Manworren and Stinson 2016).  
Regarding chronic pain, headache has been reported to be the most common in 
children and adolescents (King et al. 2011). Multiple conditions, however, may 
induce pain, and pain should thus be assessed actively in order to optimize 
comprehensive and proper treatment (Manworren and Stinson 2016, Cummings et 
al. 1996). Psychological factors as well as somatic symptoms and pain have been 
suggested to predict the development of widespread pain in adolescents (Mikkelsson 
et al. 2008). Effective pain management in children results from three steps: 1) 
recoding pain history, 2) selecting an appropriate pain assessment tool and 
completing a comprehensive pain assessment, and 3) evaluating the effectiveness of 
the treatment (Manworren and Stinson 2016). 
In general, pain in children aged six years and older should be assessed using a 
self-report (Beltramini et al. 2017). Several scales exist, but medical professionals 
need to target their use carefully (Beltramini et al. 2017, Manworren and Stinson 
2016). The Visual Analogue Scale (VAS) has been considered the gold standard for 
children aged six years and older, but the use of multiple scales is often required 
(Beltramini et al. 2017). For younger children, behavioral pain scales play a key role 
(Beltramini et al. 2017), but they carry the risk for bias, as they may be positive due 
to other unwanted conditions, such as hunger or the cold (Beltramini et al. 2017).  
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2.3.2 Pain assessment in older adults 
All older adults with chronic pain should undergo a comprehensive geriatric pain 
assessment (Reid et al. 2015). Treatment planning should always be based on an 
understanding of the patient’s treatment goals and expectations, comorbidities, and 
cognitive and functional status (Makris et al. 2014, Bicket and Mao 2015). A 5-step 
approach (self-report, pathology, behaviors, caregiver input, analgesic trial) has been 
encouraged to be adopted (Brant 2018). As suggested in the above, chronic pain in 
older adults almost always reflects a result of a chronic underlying condition (Bicket 
and Mao 2015, Larsson et al. 2017). Multi-morbidity is common in an advanced age, 
and older adults likely have multiple underlying diagnoses that contribute to pain 
(Bicket and Mao 2015). Therefore, pain in older adults is often multimodal in nature, 
and comprehensive pain assessment is required (Herr 2011, Bicket and Mao 2015).  
According to a comprehensive report by Bicket and colleagues in 2015, common 
causes of chronic pain in older adults include rheumatoid and osteoarthritis, spinal 
canal stenosis, diabetic peripheral neuropathy, trigeminal neuralgia, postherpetic 
neuralgia, peripheral vascular disease, central post-stroke pain, myofascial pain, and 
fibromyalgia (Bicket and Mao 2015). Obviously, cancer-related pain is a major pain-
causing condition in the aged population (Bicket and Mao 2015). Additionally, 
postsurgical pain may become chronic (Bicket and Mao 2015).  
The evaluation of pain intensity is known to be complex (Jensen et al. 1986, 
Breivik et al. 2008). Self-reporting has been considered to be the most reliable 
method of measuring pain (Booker and Haedtke 2016), also for older adults with 
possible cognitive impairments (Booker and Haedtke 2016, Hadjistavropoulos et al. 
2010). Several pain assessment scales exist, such as the Numeric Rating Scale (NRS), 
Visual Analog Scale (VAS), Verbal Rating Scale (VRS), and Facial Pain Scale (FPS) 
(Bicket and Mao 2015). 
Recently, Amtmann and colleagues examined the psychometric properties of a 
pain interference assessment bank (PROMIS-PI). The result of the study indicated 
a good reliability and validity of the bank. (Amtmann et al. 2010.) 
Seniors with cognitive impairment are at an increased risk of improper pain 
assessment and treatment (Bicket and Mao 2015). These individuals, however, may 
communicate in several ways to report ongoing pain (facial expressions, 
verbalization, body movements, changes in interaction with other people or the 
environment) (Bicket and Mao 2015). The DOLOPLUS-2 scale may be effective in 
identifying pain in older adults with dementia (Ando et al. 2016). The Pain 
Assessment in Advanced Dementia (PAIN-AD) scale may be used, although studies 
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regarding its reliability and validity exhibit controversy (Ersek et al. 2006). Increasing 
effort needs to be paid to the administration of multiple pain assessment scales, in 
addition to a proper assessment of functional status in everyday activities, in adults 
of an advanced age who have impaired cognition (Hadjistavropoulos et al. 2007). 
2.4 Pain coping 
2.4.1 Definition of pain coping 
Pain always includes a psychological component. Especially chronic pain produces a 
stressor to an individual, and may disturb their psychological balance 
(Andruszkiewicz et al., 2017). Children and adolescents are known to use various 
strategies to deal with prolonged or subacute pain (Weekes and Savedra 1988, 
Sposito et al. 2015, Nilsson and Willman 2016). These strategies include both 
psychological/social support, physical (e.g., relaxation methods) and 
pharmacological treatment strategies (Nilsson and Willman 2016). 
The idea of measuring pain coping is to distinguish the ongoing cognitive, 
behavioral, and emotional processes connected to pain in children and adolescents 
with recurrent or chronic pain. Additionally, the effectiveness of treatment may also 
be studied (Claar et al. 2008, Simons et al. 2015, Kashikar-Zuck et al. 2013).   
By definition, coping refers to purposeful cognitive and behavioral efforts to 
overrule the negative impacts of stress (Lazarus 1993). Cognitive strategies refer to 
changing the way an individual thinks or feels about a stressor, while behavioral 
strategies denote actually changing the way an individual deals with a stressful 
situation (Hermsen et al. 2016). It has been debated whether coping is more a 
process with the potential to change over time and across situations, or a trait that is 
more consistent in nature (Lazarus 1993). These aspects complement each other. In 
pain coping, concepts such as adaptive versus non-adaptive coping (Claar et al. 2008, 
Simons et al. 2015, Kashikar-Zuck et al. 2013) and active versus passive coping are 
often used (Edwards et al. 2016, Baastrup et al. 2016, Boschen et al. 2016). Non-
adaptive strategies (e.g., passive avoidance of a stressor, catastrophizing) have been 
suggested to associate with increased pain (Kaminsky et al. 2006). On the other hand, 
in children and adolescents, accommodative strategies and minimized 
catastrophizing have been suggested to associate with better adjustment and more 
positive outcomes (Compas et al. 2012, Eccleston et al. 2004, Jensen et al. 1991, 
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Kashikar-Zuck et al. 2013). Catastrophizing signifies negative cognitive and 
emotional schema summoned during actual or anticipated pain (Quartana et al. 2010, 
Darnall et al. 2017). 
Studies evaluating children’s pain coping in diverse medical pain-causing events 
and conditions have found similar strategies by observation. The early reports from 
the 1980s–90s already suggested strategies such as information and support seeking, 
distraction, catastrophizing/denial and avoidance, approach, emotional 
manipulation, and calming self-talk/talking with someone (Ellerton et al. 1994, 
Brown et al. 1986, Altshuler and Ruble 1989). However, importantly, patients never 
fall into one precise coping category, and coping strategies are thus always individual 
and complex to measure (Walker et al. 2008). In addition, it has been presented that, 
for example, catastrophizing may serve as both an active and a passive way of 
coping—as a form of disengagement (passive) and as an appeal for help (active) 
(Walker et al. 2008).  
The literature supports the use of cognitive-behavioral therapy in children and 
adolescents with chronic pain (Eccleston et al. 2009, Kashikar-Zuck et al. 2012, 
Palermo et al. 2010, Schanberg et al. 1997). Therapy strategies aim for improvement 
in children’s daily functioning and a reduction in emotional distress (Kashikar-Zuck 
et al. 2013).  
Although the main focus in the current study was on pediatric pain coping, 
evaluating pain coping also plays a role in geriatric pain assessment. In general, older 
adults have been reported to use fewer avoidant coping strategies and to have better 
impulse control than younger age groups (Diehl et al. 1996, Molton et al. 2008). 
Aging has long been known to modify an individual’s coping (Lazarus and DeLongis 
1983). As individuals get older, they usually become more discerning and efficient in 
the application of coping strategies (Brennan et al. 2012). Assessed by the Chronic 
Pain Coping Inventory (Jensen et al. 1995), task persistence, pacing, and coping self-
statements were reported to be the most common coping strategies in older adults 
in one study (Ersek et al. 2006). In 1997, Hopman-Rock and colleagues suggested 
that seeking social support as a coping style would be a more important predictor of 
the experienced quality of life than either pain chronicity or physical disability 
(Hopman-Rock et al. 1997). 
More negative thoughts about the consequences of pain, concerns and emotional 
pain-related representations, lower perceived self-efficacy, more catastrophizing and 
more activity avoidance, as well as an increase in pain itself have been suggested to 
be the most relevant contributors to declined physical functioning in older adults 
(Ilves et al. 2019, Hermsen et al. 2016). On the other hand, impractical coping (e.g., 
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avoidance of analgesic use) may result in a loss of activity and, thus, lead to frailty 
and disability.   
2.4.2 Significance of pain coping  
It has been suggested that children’s coping strategies may originate from the early 
child–parent interactions, manifesting either positive or negative coping models 
(Walker et al. 2008). 
Coping with pain affects children’s adjustment to pain. Especially in childhood, 
the pain coping style of chronic pain patient groups, such as catastrophizing, has 
rather consistently been found to positively relate to pain intensity and pain-related 
emotional stress (Simons et al. 2015, Edwards et al. 2016, Vervoort et al. 2010, Varni 
et al. 1996a). Additionally, baseline catastrophizing was suggested to predict pain and 
disability in a 6-month follow-up among school children (Vervoort et al. 2010). 
According to the Biobehavioral Model of Paediatric Pain, coping strategies are a key 
intervening factor in the relationship between children’s functional status and pain 
perception (Varni et al. 1996b).   
Experiences related to chronic illnesses often incite negative emotions in children 
and adolescents (Miers et al. 2007). Factors related to chronic illnesses (e.g., long 
periods of hospitalization) may have major negative effects on the child’s self-
concept (Failo et al. 2018). The importance of the family members’ support to a 
child, but also of the medical professionals’ support to the caregivers, is highlighted 
(Failo et al. 2018).  
2.4.3 The Pain Coping Questionnaire (PCQ) 
The Pain Coping Questionnaire (PCQ) was developed and validated in 1998 by Reid 
and colleagues (Reid et al. 1998). The PCQ was the first – and remains the only – 
pain coping measurement tool developed specifically for children. It has been proved 
to have good psychometric quality and is executable in multiple pain conditions 
(Reid et al. 1998, Hermann et al. 2007). Additionally, it is applicable to children from 
eight years of age onwards (Reid et al. 1998).  
In the English version of the PCQ, 39 items describing pain coping strategies 
were included. Exploratory factor analysis (data from healthy children and 
adolescents) was executed, and the items were grouped into eight coping scales 
(Information Seeking [IS], Problem Solving [PS], Seeking Social Support [SSS], 
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Positive Self-Statements [PSS], Behavioral Distraction [BD], Cognitive Distraction 
[CD], Externalizing [EXT], Internalizing/Catastrophizing [IC]) (Reid et al. 1998). 
The scales were further analyzed in the arthritis/headache sample, and three second-
order scales emerged (Approach [APP], Emotion-Focused Avoidance [EFA], 
Distraction [DIS]) (Reid et al. 1998). 
Subsequently, three studies have examined the psychometric properties of the PCQ 
and adequately validated the measurement in other languages (Catalan, Danish, 
Dutch) (Thastum et al. 1999, Bandell-Hoekstra et al. 2002, Huguet et al. 2009). The 
Danish translation suggested a seven-scale first-order structure, combining the 
original Information Seeking and Problem Solving scales (Information 
Seeking/Problem Solving [IP]) outlined by Reid and colleagues (Thastum et al. 1999, 
Reid et al. 1998). In the referred study, the structure was achieved with 36 items 
(items 1, 9, and 36 excluded) (Thastum et al. 1999). The Dutch version suggested a 
first-order structure of eight scales (Bandell-Hoekstra et al. 2002). The Catalan 
translation was studied in both school children and adults, comparing the original 
and the Danish version (Huguet et al. 2009, Reid et al. 1998, Thastum et al. 1999). 
The confirmatory factor analysis supported the seven-scale model presented in the 
Danish version (Thastum et al. 1999, Huguet et al. 2009). The coping strategies 
comprising the PCQ are presented in Table  
2.5 Pain management in children 
The pharmacokinetics and pharmacodynamics of analgesics vary with the age of the 
patient (Mazur et al. 2013). Paracetamol and NSAIDs have been regarded as 
medicines of choice in children aged three months and older (Mazur et al. 2013). 
Opioid administration should not be avoided in cancer pain (Friedrichsdorf and 
Postier 2014). Non-pharmacological methods, e.g. emotional support, playing, and 
relaxation techniques, play a key role in children (Mazur et al. 2013). 
2.5.1 Juvenile idiopathic arthritis (JIA) 
JIA is the most common chronic rheumatic disease in childhood, with pain as its 
major symptom (Giancane et al. 2017). JIA comprises a group of several clinically 
 30 
heterogeneous arthritides (Giancane et al. 2016). JIA is diagnosed based on the 
following criteria: onset prior to the age of 16 years, and arthritis persisting for longer 
than 6 weeks (Giancane et al. 2016, Prakken et al. 2011). Different JIA subtypes 
include systemic, oligoarticular, seropositive polyarticular, seronegative polyarticular, 
enthesitis-related, juvenile psoriatic, and undifferentiated (Giancane et al. 2016, Barut 
et al. 2017). 
 
Table 2.  The coping strategies comprising the Pain Coping Questionnaire (PCQ). 
Subjects were advised to report how they would act when in pain for hours or 
days (1 = Never; 2 = Hardly ever, 3 = Sometimes, 4 = Often, 5 = Very often). 
 
1 Ask questions about the problem 
2 Focus on the problem and see how I can solve it 
3 Talk to a friend about how I feel 
4 Tell myself, don't worry, everything will be OK 
5 Go and play 
6 Forget the whole thing 
7 Say mean things to people 
8 Worry that I will always be in pain 
9 Ask a nurse or a doctor questions 
10 Think about what needs to be done to make things better 
11 Talk to someone about how I am feeling 
12 Say to myself, be strong 
13 Do something fun 
14 Ignore the situation 
15 Argue or fight 
16 Keep thinking about how much it hurts 
17 Find out more information 
18 Think of different ways to deal with the problem 
19 Tell someone how I feel 
20 Tell myself it's not so bad 
21 Do something I enjoy 
22 Try to forget it 
23 Yell to let off steam 
24 Think that nothing helps 
25 Learn more about how my body works 
26 Figure out what I can do about it 
27 Talk to a family member about how I feel 
28 Say to myself things will be OK 
29 Do something active 
30 Put it out of my mind 
31 Get mad and throw or hit something 
32 Think that the pain will never stop 
33 Try different ways to solve the problem until I find one that works 
34 Let my feelings out to a friend 
35 Tell myself I can handle anything that happens 
36 Do something to take my mind off it 
37 Don't think about it 
38 Curse out loud 
39 Worry too much about it 
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The systemic form, characterized by recurrent fever and a rash, is the most common 
subtype (Barut et al. 2017). Seropositive polyarticular JIA, which is analogous to adult 
rheumatoid arthritis, is rare (Barut et al. 2017). The etiology is unclear, but an 
inflammatory response derived from both endogenous and exogenous antigens has 
been shown to play a central role in the pathogenesis (Barut et al. 2017).  
The main targets of JIA treatment are to control the pain, to preserve function 
and normal development, and to induce disease remission and manage complications 
(Barut et al. 2017). NSAIDs play a marked role in the pharmacological therapy with 
both their analgesic and their anti-inflammatory effect (Barut et al. 2017), but the 
pain treatment today mainly focuses on the control of disease activity instead of 
painkillers (Stoll and Cron 2014). 
2.6 Pain-related factors in older adults 
2.6.1 Socioeconomic factors 
The current consensus supports an increasing prevalence of persistent pain up until 
70–80 years of age (Crook et al. 1984), followed by a decline among the oldest old 
(Helme and Gibson 2001, Carmaciu et al. 2007, Brattberg et al. 1996), although the 
prevalence of pain-related conditions increase along with aging (Reid et al. 2015, 
Finne-Soveri and Pitkala 2007). The decrease in pain prevalence may be partially due 
to the older adults’ impaired visceral pain perception (Moore and Clinch 2004). 
Older adults may also adjust to pain by decreasing their locomotion, by coping with 
increased stoicism, and thinking that pain increases with aging and you should not 
complain (Finne-Soveri and Pitkala 2007). A few studies have suggested an 
increasing prevalence with increasing age (Jakobsson et al. 2003). 
Multiple studies have suggested a higher prevalence of pain in women compared 
to men (Berkley 1997, Pieretti et al. 2016). In women, higher pain intensity, more 
frequent pain, more painful areas, and longer pain duration have been reported 
(Pieretti et al. 2016). Women are also more affected by pain (Pieretti et al. 2016). 
Plasma estrogen levels have been suggested to be correlated with recurrent pain in 
women (Marcus 1995). Male gonadal hormones may also have pain-inhibiting effects 
(Ceccarelli et al. 2003). 
In 1999, Lancet published a large study regarding the association of 
sociodemographic factors with chronic pain in adults aged 25 and older (Elliott et 
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al. 1999). The prevalence of chronic pain increased when an individual was living in 
rented council accommodation and was unemployed or retired. In a Finnish study 
examining socio-economic differences in relation to pain in adults aged 40–60 years, 
women with a lower educational level as well as divorced or widowed men were 
more likely to report pain (Saastamoinen et al. 2005). Aside from these, a few studies 
have examined socioeconomic factors in relation to pain in the general adult 
population, primarily suggesting more pain in people with lower socioeconomic 
status (Riskowski 2014, Gonzalez-Chica et al. 2018).  
Specifically regarding the older age groups, an association has been presented 
between severe knee pain and lower household income, lower educational level, and 
being unmarried (Han et al. 2016). In a study by Patel and colleagues, older adults 
with a lower educational level reported more pain compared to those with a higher 
educational level (Patel et al. 2013). Additionally, a low socio-economic position has 
been reported to associate with current pain interference in a study examining a total 
of 2,533 older adults (Lacey et al. 2013). Therein, the socioeconomic position 
measures included the age when the individual left school, as well as the longest job 
and current/most recent job (Lacey et al. 2013). Furthermore, increasing 
neighborhood socioeconomic status has been found to associate with decreasing 
negative chronic pain outcomes in older adults (Fuentes et al. 2007).  
2.6.2 Morbidity 
Acute pain is a protective mechanism in response to a harmful stimulus and, apart 
from a couple of exceptions, originates from tissue damage or a somatic disease 
(Swieboda et al. 2013). Therefore, the somatic aspects and pain-causing morbidities 
were not considered herein.  
However, especially chronic pain is frequently associated with multiple disabilities 
(Alschuler et al. 2016). Chronic pain negatively interferes with physical functioning 
and participation in everyday life activities (Hartikainen et al. 2005, Rapo-Pylkko et 
al. 2015, Ehde and Hanley 2006). In older adults, decreased physical functioning may 
result in, for instance, an increased risk of falls. On the other hand, pain acceptance 
has been suggested to associate with lower pain intensity and lower physical disability 
(McCracken 1998). 
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2.6.3 Psychological and emotional factors  
The pain experience is always multidimensional, comprising of not only 
physiological but also psychological aspects and subjective perceptions (Swieboda et 
al. 2013). Emotional aspects, such as suffering, are always present (Swieboda et al. 
2013, IASP 2018).  
Depression and depressive symptoms have long been known to associate with 
persistent pain among the older population (Han et al. 2016, Zis et al. 2017, Roy and 
Thomas 1986, Sanders et al. 2015, Reid et al. 2003). A 13-year follow-up examining 
older adults in pain (N=1,528, mean age 67.9 years) found an association between 
pain and depression over the follow-up, and neither aging itself nor frailty changed 
the association (Sanders et al. 2015). A two-year follow-up investigating a 
longitudinal relationship between depression, anxiety, and pain in 545 patients with 
severe lower extremity trauma highlighted the role of a negative mood (anxiety) in 
the persistence of acute pain (Castillo et al. 2006).  
Recently, Karjalainen and colleagues examined pain in Finnish older adults with 
or without diabetes, suggesting a higher prevalence of pain related to diabetes in both 
women and men (Karjalainen et al. 2018). In their study, depressive symptoms and 
the number of comorbidities were found to associate with frequent pain (Karjalainen 
et al. 2018).  
An association between sleep disturbances and pain has been suggested (Vitiello 
et al. 2009, Smith and Haythornthwaite 2004). Sleep disturbances may have a key 
role in the development and maintenance of chronic pain (Finan et al. 2013). Vitiello 
and colleagues have suggested long-term improvements in chronic pain with short-
term improvements in sleep in adults over 60 years of age (Vitiello et al. 2009). 
Sadness has been reported to be more prevalent among older adults in pain than 
among those with no pain (Rapo-Pylkko et al. 2016), and loneliness has recently been 
highlighted as a predictor of many health-affecting concerns (insomnia, pain, fatigue) 
considering older adults (Jaremka et al. 2013). A lack of social support or contacts 
has been suggested to associate with pain in multiple studies (Baker et al. 2017, 
Alonso and Coe 2001, Bradbeer et al. 2003, Gil et al. 1987), but the protective effects 
of a social network on morbidity and mortality outcomes have been evident for a 
long time (Kawachi and Berkman 2001, Berkman et al. 2000, Holt-Lunstad et al. 
2010). 
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2.6.4 Lifestyle aspects 
Obesity and pain both comprise a burden on the individual, the healthcare system, 
and society (Taylor et al. 2014). The association between pain and obesity in older 
adults has been demonstrated in several studies (Heim et al. 2008, McCarthy et al. 
2009, Ray et al. 2011, Okifuji and Hare 2015). Obesity is a major risk factor for 
osteoarthritis (Kulkarni et al. 2016), for example, and osteoarthritis is one of the 
leading pain-causing conditions in older adults (Peat et al. 2001). A significant 
association between central obesity and chronic pain has been shown to exist among 
community-dwelling adults aged 70 and older (OR 2.03, 95% CI 1.36–3.01) (Ray et 
al. 2011). Therein, chronic pain was defined as pain in at least one of eight 
predetermined locations at least some of the time with at least moderate severity 
over the preceding three months. In the study, the prevalence of pain exceeded 50% 
(Ray et al. 2011). 
In a study examining the prevalence of metabolic syndrome (MetS) in patients 
with fibromyalgia, a 5.56-fold risk of MetS was discovered (Loevinger et al. 2007). 
Additionally, Duruöz and colleagues have found a significant difference in age and 
disease duration between chronic lower back pain patients with and without MetS 
(Duruoz et al. 2012). The consensus supports the consideration of the MetS risk 
factors in chronic lower back pain patients (Duruoz et al. 2012, Ha 2011). 
Neuropathic pain is closely related to MetS, which is determined as the presence of 
hyperglycemia (Callaghan and Feldman 2013). It has been shown that diabetics are 
more likely to have neuropathy if other components of MetS are also present 
(Isomaa et al. 2001), and half of all diabetics with neuropathy experience neuropathic 
pain (Abbott et al. 2011). 
Studies examining the association of smoking and alcohol consumption with pain 
are scarce. A few larger studies have examined smoking and chronic pain in adults, 
suggesting smoking as a risk factor (Shiri et al. 2010, Shiri et al. 2007, Shi et al. 2010). 
Whether alcohol consumption increases or decreases subjective pain is unclear 
(Brennan and Soohoo 2013, Castillo et al. 2006). 
Patients with lower back pain are recommended to remain physically active 
(Bekkering et al. 2003, Waddell et al. 1997), and different exercise methods have 
been actively used in the treatment of lower back pain (Chan et al. 2011, Suni et al. 
2006). However, in 2012, a one-year follow-up study investigating the correlation 
between leisure time physical activity (LTPA) and lower back pain among cleaners 
(N=188) showed no correlation with and no positive effect of LTPA on pain during 
an episode of acute lower back pain (Jespersen et al. 2012). Additionally, in a meta-
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analysis considering an association between lifestyle risk factors and lumbar radicular 
pain, high levels of LTPA were associated with an increased risk of lumbar radicular 
pain (Shiri et al. 2007).  
Intrinsically, the nature of the pain needs to be determined when evaluating the 
treatment options. Yet, despite the contradictory study results, the overall consensus 
recommends exercise especially for musculoskeletal pain patients (Meng and Yue 
2015, O'Connor et al. 2015). 
2.7 Pain management in older adults 
2.7.1 Recommendations 
The overall consensus highlights the under-assessment, under-diagnosis, and under-
treatment/mistreatment of persistent pain in older people (Gagliese and Melzack 
1997, Tracy and Sean Morrison 2013, Veal et al. 2014). Proper assessment constitutes 
a basis for optimal pain management (Malec and Shega 2015). The treatment should 
focus on pain reduction,  improvements in functioning, and an enhanced quality of 
life (AGS 2009, Fine 2012). According to the AGS, it is unrealistic to expect that the 
pain will completely disappear in all cases (AGS 2009). 
 Older adults may have different stages of cognitive impairment and 
dementia, which  need to be taken into account in pain assessment and management 
planning, as cognitive impairment has been demonstrated to be a risk factor for, for 
instance, receiving unscheduled pain medication or fewer pain medication (Nygaard 
and Jarland 2006, Reynolds et al. 2008). Furthermore, difficulties in the physical 
accessibility of treatment, the cost of medication, multimorbidity, and polypharmacy 
may cause challenges in older adults’ pain management (McCleane 2007). 
Importantly, age-related alterations in pharmacokinetics and pharmacodynamics 
(reduced muscle mass, increased body fat, decreased renal and hepatic function, etc.) 
may cause multiple challenges in pharmacological pain management (Fine 2012, 
AGS 2009). 
Analgesic administration should follow the principle of “start slow and go slow” 
(AGS 2009). According to a large literature review regarding pain management in 
the older adult population (92 studies from 1990 to 2014), paracetamol was 
considered to be the first-line pharmacological therapy, followed by NSAIDs in the 
absence of contraindications (Makris et al. 2014). The use of COX-2 selective 
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inhibitors has been associated with fewer gastrointestinal adverse effects compared 
to other NSAIDs, but the other types of NSAID-related toxicities are the same (Fine 
2012, By the American Geriatrics Society Beers Criteria Update Expert 2019). Non-
pharmacological modalities always need to be added to pharmacological ones 
(Makris et al. 2014, Abdulla et al. 2013). Opioid administration may be considered 
with moderate to severe cancer and non-cancer pain, but only after precise individual 
deliberation and with careful monitoring (Abdulla et al. 2013, Naples et al. 2016, 
Huang and Mallet 2013). Neuropathic conditions should be managed with 
neuropathic drugs (Pickering et al. 2016). 
Long-term opioid administration for chronic non-cancer pain remains 
controversial (Galicia-Castillo 2016). Multiple studies have suggested tramadol or 
other weak opioids as the first-line opioid for acute and chronic pain (Makris et al. 
2014, Naples et al. 2016, Reid et al. 2015). On the other hand, a few studies have 
proposed a preference of low-dose strong opioids for older adults (Huang and Mallet 
2013, Guerriero 2017, van Ojik et al. 2012). For neuropathic conditions, 
gabapentinoids and especially SNRIs have been suggested as preferred over TCAs 
(Pickering et al. 2016). 
However, expert groups have also issued warnings concerning several analgesics 
in special patient groups. The American Geriatrics Society’s (AGS) Beers Criteria for 
potentially inappropriate medication use in older adults (the 2019 update) highlights 
the use of non-pharmacological methods in older adults, as the administration of all 
analgesics may comprise challenges among older people (AGS 2009). According to 
the Beers Criteria, NSAIDs should be avoided in long-term use in older adults, and 
SNRIs, TCAs, and tramadol should be used with caution (By the American 
Geriatrics Society Beers Criteria Update Expert 2019). The AGS also suggests the 
avoidance of antiepileptics, TCAs, SNRIs, and opioids in individuals with a history 
of falls and fractures (By the American Geriatrics Society Beers Criteria Update 
Expert 2019). 
2.7.2 Prevalence studies considering analgesics administration in older 
adults 
Prevalence studies considering the administration of analgesics among older adults 
in a population-based setting are scarce (Rapo-Pylkko et al. 2016, Nawai et al. 2017, 
Veal et al. 2015, Pokela et al. 2010, Koponen et al. 2013). Some studies regarding the 
use of analgesics among older adults exist (Enthoven et al. 2014). Steinman and 
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colleagues studied alterations in analgesics use among older adults in the USA 
between 1999 and 2010 (mean age 75 years) (Steinman et al. 2015). They found that 
opioid use had more than doubled, paracetamol use had remained stable, NSAID 
use had decreased slightly, and the use of gabapentinoids had increased slightly 
during the follow-up period (Steinman et al. 2015). In 2010, it was presented that 
23% of community-dwelling older adults in Finland took analgesics on a daily basis 
(Pokela et al. 2010).  
Halla-aho and colleagues studied the use of analgesics for musculoskeletal pain 
among home-dwelling older adults in two cohorts, 1999 vs. 2009 (Halla-aho 
musculoskeletal). In the 1999 cohort, 36% had used prescribed analgesics for 
interfering joint pain and 38% for interfering back pain, whereas the proportions in 
the 2009 cohort were 42% and 48%, respectively (Halla-aho et al. 2013).  
The use of over-the-counter analgesic may induce remarkable bias in the 
estimates. Referring to what is presented in the literature, the overall amount of 
NSAIDs used most likely exceeds what is presented in the prevalence studies, when 
combined with the amount obtained over the counter (Enthoven et al. 2014). In 
2002, it was estimated that over-the-counter administration would have accounted 
for 54% of all ibuprofen sold in Finland (Turunen et al. 2005). In the referred study, 
the setting was questionnaire-based (“how often do you use prescribed/over-the-
counter analgesics?”), and the participants were randomly selected citizens (N = 
3,282) (Turunen et al. 2005). More recently, in 2015, Sarganas and colleagues studied 
analgesics use in a population-based setting and presented the following prevalence 
figures in adults aged 65 years and older: overall analgesics use 19.5%–20%, over-
the-counter analgesics 3.7%–4.5%, and prescribed analgesic 13%–16 % (Sarganas et 
al. 2015). However, regarding older adults, a strong association between increased 
age and the use of only prescribed analgesics was found (Sarganas et al. 2015). 
A recent study pointed out a concern as to whether the monitoring of the proper 
dose and analgesic selection in older adults is sufficient, as 30% of the study subjects 
with moderate to severe pain felt they needed stronger pain medication, and 15% 
were concerned they were using too much pain medication (Nawai et al. 2017). 
Additionally, according to Karttunen and colleagues, 41% of community-dwelling 
older adults with chronic musculoskeletal pain hoped a physician would pay more 
attention to their pain management (Karttunen et al. 2014). According to another 
study by Karttunen and colleagues, only 15% of Finnish older adults with chronic 
pain were taking analgesics regularly (Karttunen et al. 2015). 
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2.7.3 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drug is a term referring to drugs with analgesic, 
anti-inflammatory, antithrombotic, and antipyretic effects. The mechanisms behind 
both the desired and adverse effects originate from the inhibiting effect of NSAIDs 
on cyclooxygenase enzymes (COX-1 and/or COX-2), which are involved in 
prostanoid (prostaglandins, prostacyclins, thromoxanes) synthesis (Wehling 2014, 
Schjerning et al. 2009, Harirforoosh and Jamali 2009, Harirforoosh et al. 2013). In 
particular, NSAIDs and selective COX2 inhibitors inhibit cyclooxygenase through 
competing with arachidonic acid for the active site of the enzyme, thus inhibiting its 
conversion to prostaglandin H (Jozwiak-Bebenista and Nowak 2014). The term 
NSAIDs often includes propionic acid derivatives (e.g. ibuprofen, naproxen), acetic 
acid derivatives (e.g. ketorolac, indomethacin, diclofenac), oxicams, fenamates, as 
well as second-generation NSAIDs, namely selective COX-2 inhibitors 
(Harirforoosh and Jamali 2009). In addition, the oldest NSAID, salicylate (e.g. 
acetylsalicylic acid) has originally been included (Harirforoosh and Jamali 2009). 
According to the literature, NSAIDs are a major cause of drug-related morbidity 
among the older population (Wehling 2014). Contradictorily, the majority of the side 
effects of NSAIDs are related to inflammation (Harirforoosh and Jamali 2009), as 
NSAIDs develop a change in the balance between COX-1 and COX-2 activities in 
the body (Harirforoosh et al. 2013). For example, the effects of non-selective 
NSAIDs on the gastrointestinal tract originate from the inhibition of the protective 
effects of cyclooxygenases on the gut mucosa (Wehling 2014, Sostres et al. 2010). 
Furthermore, the gastrointestinal side effects are associated with the expression of 
nitric oxide, which is implicated in inflammatory conditions (Harirforoosh et al. 
2013). It has been estimated that gastrointestinal ulcers may occur in several percent 
of all chronic unprotected, high-dose NSAID users (Wehling 2014). The use of 
selective COX-2 inhibitors has been reported to reduce the risk of gastrointestinal 
complications (e.g. perforation, motility impairment, bleeding) significantly (Sostres 
et al. 2010, Jarupongprapa et al. 2013). The main risk factors of gastrointestinal 
complications related to NSAID use include a previous peptic ulcer, age, and 
concomitant aspirin use (Sostres et al. 2010).  
NSAIDs also have renal side effects, which can be as severe as acute or chronic 
kidney injury (Musu et al. 2011). The prevalence of renal adverse effects has been 
estimated to be 1%–5% among NSAID users (Harirforoosh and Jamali 2009). 
Various forms of renal failure have been reported: for example, sodium retention, 
hyperkalemia, and papillary necrosis (Breyer et al. 2001, Whelton and Hamilton 
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1991). Changes in renal function may influence the cardiovascular system 
(Harirforoosh and Jamali 2009), such as sodium retention resulting in arterial 
hypertension (Wehling 2014). The cardiovascular adverse effects include fluid 
retention, increasing blood pressure, heart failure, and atherosclerotic events 
(Wehling 2014, McGettigan and Henry 2006, Trelle et al. 2011). The effects of 
NSAIDs on ion channels (Ca2+ induced K+ channels) have been thought to be one 
explanation of the cardiotoxicity (Harirforoosh and Jamali 2009, Brueggemann et al. 
2010). It has been estimated that chronic high-dose NSAID use in the long term 
may triple the risk of cardiovascular events (Wehling 2014). Additionally, increased 
mortality in association with NSAID use has also been reported (Gislason et al. 
2009). It has been presented that, aside from the gastrointestinal effects, COX-2 
selective inhibitors do not differ from other NSAIDs in terms of other drug-related 
toxicities (Fine 2012). 
A 13-fold increase in the risk of hemorrhagic peptic ulcer disease has been 
demonstrated in concomitant use of NSAIDs and warfarin (Fine 2009). 
Concomitant use of NSAIDs and diuretics has been shown to double the risk of 
hospitalization for congestive heart failure in adults aged 55 years and older 
(Heerdink et al. 1998). In addition, the use of concomitant SSRIs strongly increases 
the risk of gastrointestinal bleeding (de Jong 2003). 
NSAIDs may be considered for short-term musculoskeletal or inflammatory pain 
if contraindications are not present (Fine, AGS, Makris, Abdulla). The concomitant 
use of a proton-pump inhibitor is recommended, although recent studies have 
suggested that proton-pump inhibitors are unable to prevent NSAID-related 
gastrointestinal adverse effects (Scarpignato et al. 2015). 
Topical NSAIDs have been regarded as a safer and effective alternative to 
systemic NSAIDs in older adults, especially in local arthrosis and arthritis-related 
pain, for example, but the risk of systemic adverse effects is also present with topical 
products (Makris et al. 2010). 
A few studies have estimated NSAID administration in older adults, comprising 
diverse study settings. In community-dwelling adults aged 70 and older, the 
prevalence of regular NSAID use has been reported to be 8% and that of as-need 
use 3% (NSAID definition: selective COX-2 inhibitors, non-selective COX-1 and 
COX-2 inhibitors), and the mean treatment duration was almost 5 years (Gnjidic et 
al. 2014). In a large population-based study published in 2010, Vandraas and 
colleagues retrieved all NSAID prescriptions (NSAID definition: all Mo1A drugs 
within the World Health Organization Anatomical Therapeutic Chemical  
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classification system [ATC], excluding glucosamine, nabumetone, and selective 
COX-2 inhibitors) for chronic gout, rheumatoid arthritis/ankylosing spondylitis, 
and/or severe coxarthrosis and gonarthrosis of community-dwelling adults aged 60 
years or older from the nationwide Norwegian Prescription Database (Vandraas et 
al. 2010). According to their results, 7% of the seniors had received a NSAID 
prescription for these conditions during a one-year interval (Vandraas et al. 2010). 
According to a study by Pilotto and colleagues, 25% of adults over 65 years of 
age had used NSAIDs (one third chronically) (Pilotto et al. 2003). In a Canadian 
retrospective study using Alberta Blue Cross Database data of over 60,000 aged 
citizens, the prevalence of NSAID use was 27% (Hogan et al. 1994). However, 
acetylsalicylic acid, most commonly used for an antithrombotic indication, was 
included in these two analyses. Selective COX-2 inhibitors were not included. In a 
study reviewing 16 NSAID use–related papers, the prevalence of a daily 
administration of NSAIDs was evaluated to be as high as 20%–30% among older 
adults (Findley and Bulloch 2015). The definition of NSAIDs has proved crucial in 
comparing prevalence studies. Originally, acetylsalicylic acid has been considered a 
member of the NSAID family, but it has not been included very often in newer 
studies. Additionally, new-generation NSAIDs, COX-2 selective inhibitors, have 
been included in several newer studies. Examples of studies evaluating the 
prevalence of NSAID use in a population-based setting are presented in Table 3. 
2.7.4 Paracetamol (acetaminophen) 
Paracetamol is well tolerated, but increasing numbers of paracetamol-induced liver 
intoxications (dose-dependent) have been reported (Jozwiak-Bebenista and Nowak 
2014).  
The mechanism of action of paracetamol is unclear, but it has been suggested to 
act as a factor reducing a ferryl protoporphyrin IX radical cation within the 
peroxidace site of the cyclooxygenace enzyme (Jozwiak-Bebenista and Nowak 2014, 
Anderson 2008). This ferryl protoporphyrin IX radical cation is needed in tyrosine-
385 oxidation into tyrosine-385 radicals, which are needed in the conversion of 
arachidonic acid to prostaglandin H (Anderson 2008).  
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The adverse effects of paracetamol are less frequent compared to NSAIDs, which 
may be partially due to the fact that paracetamol mostly acts centrally and not much 
peripherally (Anderson 2008). In the central nervous system, it influences pain 
stimulus conduction through the spinal cord to the thalamus and the cerebral cortex 
via the COX, the descending serotoninergic pathways, the L-arginine/NO-pathway, 
and the cannabinoid system (Jozwiak-Bebenista and Nowak 2014). Also, 
paracetamol only weakly inhibits COX-1 (Jozwiak-Bebenista and Nowak 2014). It 
has a markedly stronger effect on COX-2, which, however, may carry a risk of coxib-
like adverse effects, such as hypertension, myocardial infarction, and renal failure, in 
long-term and high-dose use (Jozwiak-Bebenista and Nowak 2014). 
Paracetamol has long been considered the drug-of-choice in geriatric pain 
management (Nawai et al. 2017, Makris et al. 2014, Abdulla et al. 2013). Recently, 
however, physicians have been encouraged to consider not prescribing paracetamol 
for patients with lower back pain and osteoarthritis due to possible inefficacy 
(Machado et al. 2015). Its possible inefficacy in chronic pain conditions may be 
considered as one major ‘adverse effect’ (Machado et al. 2015). 
In 2013, a Finnish study presented the prevalence of regular or as-needed 
paracetamol use to be 31% among community-dwelling older adults over 75 years 
of age (Koponen et al. 2013). In this study, paracetamol was the most prevalent 
analgesic in frail (54%) and pre-frail (34 %), but not in robust (19%) individuals, who 
predominantly used NSAIDs (25%) (Koponen et al. 2013). In a recent study 
examining the analgesics administration profile among community-dwelling older 
adults (over 70 years of age) in the USA, 28% of the studied individuals had used 
paracetamol during the preceding two weeks (Nawai et al. 2017). Therein, 
paracetamol was the most prevalent analgesic (Nawai et al. 2017). 
2.7.5 Opioids 
Opioid administration is a worrying and growing phenomenon worldwide; the 
inappropriate use of prescribed opioids is also referred to as an epidemic 
(Manchikanti et al. 2012). Opioid-related overdose deaths have been reported to 
have doubled in the USA from 2000 to 2014 (Rudd et al. 2016). A significant 
proportion of the increase in deaths was associated with the addition of long-acting 
oxycodone to the drug formulary (Dhalla et al. 2009). The opioid crisis is no longer 
regarded as a medical problem, but a public health crisis (Pergolizzi et al. 2017).  
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Several matters need to be considered when prescribing opioids to older adults. 
The challenges and adverse effects related to opioid administration are emphasized 
in later life due to age-related physiological changes, cognitive impairment, multi-
morbidity, and polypharmacy (Makris et al. 2014). The physiological changes include, 
for example, altered renal function, changes in absorption, and frailty (Makris et al. 
2014, Reid et al. 2011). Cognitive impairment may pose a challenge in pain 
assessment (Makris et al. 2014), but decreased mental health functioning has been 
reported.  
When opioids are prescribed, the appropriate dose needs to be carefully titrated 
(Abdulla et al. 2013). Both desired and adverse effects need to be monitored regularly 
(Abdulla et al. 2013, Huang and Mallet 2013, O'Mahony et al. 2015). Adverse effects 
are relatively frequent, potentially with severe consequences (Papaleontiou et al. 
2010, Benyamin et al. 2008, Pergolizzi et al. 2017, Pergolizzi et al. 2008). Common 
reported adverse effects include dizziness (potentially leading to falls), constipation, 
nausea and vomiting, respiratory depression, pruritus and urinary retention, and a 
decline in cognitive function (Papaleontiou et al. 2010, Benyamin et al. 2008, 
Pergolizzi et al. 2008, Schug et al. 1992). Older people are especially prone to 
developing confusion and cognitive decline when using opioids. In addition, the risk 
of falls and fractures comprises a major risk in older adults (Perttila et al. 2018). It is 
important to mention that the tendency to develop opioid-related tolerance, 
according to reports, may develop as rapidly as within days (Collett 1998). 
Three opioid receptor peptides have been identified: the mu- (MOR), delta- 
(DOR), and kappa-opioid receptor (KOR) (Pergolizzi et al. 2017, Stein 2016). The 
majority of the commonly used opioid agonists have the greatest affinity to MORs, 
and the KOR and DOR effects are merely dose-dependent (Pergolizzi et al. 2017). 
All receptors are known to activate the K+ and to inhibit the Ca2+ channels 
(Pergolizzi et al. 2017). K+ channel activation leads to neuron hyperpolarization, 
thereby raising the pain threshold (Pergolizzi et al. 2017). Ca2+ current inhibition, 
instead, leads to a decreased release of excitatory neurotransmitters (Pergolizzi et al. 
2017, Zhang et al. 2005). Thus, all receptors mediate analgesia (Stein 2016). The 
effects of MORs also include euphoria, constipation, respiratory depression, and 
reduced inflammation, while the effects of DORs entail convulsions, anxiolysis, and 
constipation and effects of KORs diuresis, dysphoria, and reduced inflammation 
(Stein 2016). 
Opioids have traditionally been classified as weak (tramadol, codeine) and strong 
(e.g. morphine, oxycodone), although the classification has been less used in recent 
reports (Rosenblum et al. 2008). Morphine is metabolized in the liver, and both 
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important metabolites, morphine-6-glucuronide (M6G) and morphine-3-
glucuronide (M3G), have significant effects in the body (Prostran et al. 2016). M6G 
functions as an analgesic, and M3G may cause neuroexcitatory effects (Prostran et 
al. 2016). Most opioids are metabolized by CYP450 isoenzymes (Gianni et al. 2009). 
Oxycodone is a semi-synthetic opioid with 1:2 equivalence to morphine 
(Ordonez Gallego et al. 2007). No significant difference has been found in the 
analgesic efficacy of oxycodone versus morphine in cancer pain (Kalso and Vainio 
1990, Heiskanen et al. 2000). 
In addition to binding to opioid receptors, tramadol inhibits serotonin and 
noradrenaline receptors (Chau et al. 2008) and may cause SNRI-like adverse effects, 
such as hyponatremia (By the American Geriatrics Society Beers Criteria Update 
Expert 2019).  
Individual variability in codeine metabolism should be recognized (Chau et al. 
2008). Codeine is a pro-drug and has a 200-fold weaker affinity to MOR compared 
to morphine (Chidambaran et al. 2017). Eighty percent of codeine is inactivated by 
CYP3A4, and only 5%–10% is O-demethylated to morphine by CYP2A6 
(Chidambaran et al. 2017). More than a hundred polymorphisms of CYP2A6 have 
been identified (Chidambaran et al. 2017). The polymorphisms comprise major 
challenges in the prediction of an individual’s clinical response to codeine, as 
individuals may be poor, intermediate, or ultra-rapid codeine metabolizers 
(Chidambaran et al. 2017). 
Buprenorphine has, in some studies, been presented as being preferred for older 
adults due to its favorable pharmacokinetic properties (Huang and Mallet 2013). 
Buprenorphine is a partial agonist of, but has a high affinity to MOR (Chen et al. 
2014). Therefore, the MOR-mediated adverse effects, such as respiratory depression, 
develop to a lesser extent in comparison to other opioid receptor agonists. 
Additionally, buprenorphine slowly dissociates from the MOR, producing a 
prolonged duration of action (Chen et al. 2014). Furthermore, as buprenorphine is a 
KOR antagonist, the KOR-mediated effects, such as dysphoria, are diminished 
(Chen et al. 2014). For the past decade, a buprenorphine patch has been probably 
the most prevalent opioid among older adults (Mercadante et al. 2016). On the other 
hand, Lalic and colleagues recently found that transdermal opioid administration was 
the strongest predictor of opioid use persistence in older adults aged 65–84 years 
(OR 4.24, 95% CI 3.85–4.68), as well as in adults over 85 years of age (OR 3.47, 95% 
CI 3.02–3.98). In the oldest old, initiation on a strong opioid also strongly predicted 
persistent use. (Lalic et al. 2018.) 
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The advantages of using opioid receptor antagonists have been discussed (Holzer 
2010, Powell et al. 2002, Hoskin and Hanks 1991). A study considering oral 
alvimopan for the shortening of postoperative ileus, subcutaneous methylnaltrexone 
for the reduction of constipation, and oral naloxone with oxycodone for pain 
treatment, showed a favorable adverse effect profile in all three entities (Holzer 
2010). Therein, the analgesic effect was reported to be constant. In addition, the 
rewarding effects of morphine have been suggested to be prolonged when combined 
with an ultra-low dose antagonist (Powell et al. 2002). In 2014, a favorable profile of 
the prolonged-release oxycodone/naloxone combination in comparison to 
prolonged-release oxycodone in terms of efficacy, rates of observed constipation, 
tolerability, and cost-effectiveness was reported (Burness and Keating 2014). 
Opioid-induced adverse reactions were recently reported as being frequent in 
male patients of the Korea Veterans Hospital. The odds of adverse reactions 
increased significantly in long-term use. Compared to codeine use, individuals using 
morphine and oxycodone had 653 and 473 % increased odds of adverse reactions. 
(Kim et al. 2018.) 
The decision as to whether a weak or strong opioid should be selected when the 
need for an opioid in an older adult arises is complex due to the lack of evidence 
regarding safety and tolerability (Prostran et al. 2016). Recent suggestions have 
highlighted the importance of proper assessment of the pain quality upon which the 
selection should be based (Malec and Shega 2015).  
A recent Canadian recommendation regarding opioid therapy for non-cancer 
pain suggested the following: the optimization of non-opioid pharmacotherapy and 
non-pharmacological therapy; a trial of opioids (rather than continued therapy) for 
patients with no history of substance abuse or any other active psychiatric condition; 
avoiding the use of opioids in patients with active substance abuse or a history 
thereof; stabilizing the psychiatric disorder before the trial of opioids in patients with 
active psychiatric disease; adjusting the morphine-equivalent daily dose to less than 
50–90 mg for patients who are beginning the opioid therapy for chronic non-cancer 
pain; rotation to another opioid in patients with current opioid use but persistent 
problematic pain and/or problematic adverse effects; tapering opioids to the lowest 
effective dose in chronic non-cancer pain patients using the equivalent of 90 mg 
morphine or more daily; a formal multidisciplinary program for patients with chronic 
non-cancer pain who are using opioids but experiencing serious challenges in 
tapering (Busse et al. 2017).  
Opioids have also proved effective in neuropathic pain, but only as a second- 
(tramadol) and third-line therapy (strong opioids) (Finnerup et al. 2015). Opioid-
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related adverse effects and the development of tolerance need to be taken into 
account in pain management (Abdulla et al. 2013). 
To date, studies evaluating opioid use in older adults have been scarce. During 
the current decade, it has been estimated that approximately 5%–9% of community-
dwelling older adults use opioids chronically for non-cancer pain (Campbell et al. 
2010, Karp et al. 2013, Nawai et al. 2017, Hamina et al. 2017a). In 2011, Marcum 
and colleagues presented the prevalence of analgesics administration among 
community-dwelling seniors with symptomatic lower limb osteoarthritis (Marcum et 
al. 2011). Half of the participants in their study reported taking at least one non-
opioid analgesic, while one in ten reported taking some opioid analgesic (Marcum et 
al. 2011).  
Pitkälä and colleagues examined the change in opioid administration among 
institutionalized older adults over an eight-year follow-up (2003–2011). The 
prevalence of regular opioid use doubled within 8 years in both nursing homes (12% 
vs. 23%) and assisted living facilities (9% vs. 17%). (Pitkala et al. 2015.) The use of 
opioids had increased further in a subsequent 6-year follow-up (Roitto et al. 2019). 
Furthermore, in 2014, Veal and colleagues studied opioid consumption among older 
adults living in a fulltime care facility and found that 28% had used opioids regularly, 
and only half of these subjects with optimized paracetamol. The most prevalent 
opioid was immediate-release oxycodone (15% of all subjects), followed by a 
buprenorphine patch (13%) and codeine, with or without a combined analgesic (8%). 
(Veal et al. 2014.) 
2.7.6 Neuropathic drugs 
The prevalence of neuropathic pain is known to increase with age (Schmader et al. 
2010). The evaluation of pain quality and the recognition of the neuropathic 
component of pain is important, as higher pain and disability scores reduce the 
quality of life and a higher prevalence of psychological disorders has been shown to 
associate with neuropathic pain (Smith and Torrance 2012). The current study 
focused on gabapentinoids (pregabalin, gabapentin) and tricyclic antidepressants 
(TCAs; amitriptyline, nortriptyline). However, since the serotonin-noradrenaline 
reuptake inhibitors (SNRIs) duloxetine and venlafaxine have recently become 
preferred in managing older adults’ neuropathic pain (Finnerup et al. 2015), they are 
also briefly discussed below. 
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Gabapentin was originally developed as an anticonvulsant, and its analgesic effect 
was presented 20 years ago (Mellick et al. 1995). Gabapentinoids are particularly 
effective in neuropathic pain (Toth 2014). Both gabapentin and pregabalin were 
originally designed as GABA analogs, but neither has any significant effect on 
GABA levels (Lanneau et al. 2001, Patel and Dickenson 2016). The precise 
mechanism of action of gabapentinoids remains unclear, but it is assumed that they 
bind to calcium channel subunits that regulate the activation and inactivation of 
calcium currents (Patel and Dickenson 2016, Hobom et al. 2000), thereby inhibiting 
the release of neurotransmitters in neuronal tissues (Chincholkar 2018). 
Gabapentinoids have been reported to associate with increased sedation, dizziness 
(potentially leading to falls), and visual disturbances (Mathiesen et al. 2014) but are 
still considered well tolerated (Toth 2014). Gabapentinoids have been suggested to 
double the risk of falls among older people (Mukai et al. 2019). They are excreted 
through the kidneys, thus accumulating in renal dysfunction (Toth 2014).  
Tricyclic antidepressants and SNRIs have been reported to be efficacious in 
multiple chronic pain conditions, such as diabetic neuropathy and migraine (Jackson 
and St Onge 2003). A recent meta-analysis including 23 RCTs specified the drug-
related adverse effect risk profiles (Riediger et al. 2017). The common side effects 
were concluded to be as follows: drowsiness/dizziness, dry mouth, constipation, 
headache and weight gain for amitriptyline and nortriptyline; nausea/vomiting and 
drowsiness/dizziness for venlafaxine; and nausea/vomiting, dizziness, fatigue, 
gastrointestinal symptoms, and headache for duloxetine (Riediger et al. 2017, 
Sansone and Sansone 2008). A recent large systematic review and meta-analysis 
evaluated the overall tolerability of antidepressants used for chronic pain as being 
high (Riediger et al. 2017). 
The analgesic effects of both TCAs and SNRIs involve binding to noradrenaline 
and serotonin transporters, leading to an increase in these neurotransmitters in the 
synaptic cleft (Obata 2017). In particular, the noradrenaline reuptake inhibition–
mediated activation of the alpha2-adrenergic receptors in the spinal cord dorsal horn 
inhibits hyperalgesia and allodynia (Obata 2017). The increase in serotonin in the 
synaptic cleft plays an auxiliary role, but the precise mechanism of action is not clear 
(Obata 2017). It has been suggested that serotonin inhibits the generation of painful 
stimuli in the central nervous system, but, contrarily, also increases pain transmission 
from the periphery (Ferjan and Lipnik-Stangelj 2013). 
Amitriptyline inhibits serotonin reuptake more than it does noradrenaline uptake, 
whereas nortriptyline has more effect on noradrenaline (Sansone and Sansone 2008). 
Venlafaxine inhibits serotonin reuptake at low doses and noradrenaline uptake at 
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high doses (Sansone and Sansone 2008). Duloxetine has been suggested to inhibit 
the reuptake of both serotonin and noradrenaline relatively equally and has thereby 
proved very effective (Sansone and Sansone 2008). 
The NNT (number needed to treat) for neuropathic drugs varies significantly 
between disease states (Finnerup et al. 2015), which may be considered a problem 
when using these drugs. According to what was presented in 2015 in the updated 
recommendations for the treatment of neuropathic pain in adults (not only older 
people) by Finnerup and the IASP Neuropathic Pain Special Interest Group, the 
combined NNTs for neuropathic drugs were: 7.71 for pregabalin (95% CI 6.5–9.4), 
7.16 for gabapentin (95% CI 5.9–9.1), 6.40 for serotonine-noradrenaline reuptake 
inhibitors (95% CI 5.2–8.4), and 3.57 for TCAs (95% CI 3.0–4.4) in the adult 
population (Finnerup et al. 2015). 
Prevalence studies regarding neuropathic drug administration among older adults 
are extremely scarce, and a literature search did not find an even relatively recent 
study that would have comprehensively evaluated TCA, gabapentinoid, or SNRI use 
for a pain indication among community-dwelling older adults.  
A few existing guidelines suggest gabapentinoids and SNRIs rather than TCAs 
for older adults due to the major anticholinergic effects of TCAs (Pickering et al. 
2016, McGeeney 2009). SNRIs (duloxetine, venlafaxine) have recently gained more 
favor among older adults (Pickering et al. 2016). The favorable effect of duloxetine 
in the treatment of ostheoarthritis pain in older adults has been suggested (Abou-
Raya et al. 2012). Additionally, Karp and colleagues recently encouraged the use of 
duloxetine in the management of comorbid depression and chronic lower back pain 
in older adults (mean age 71 years) (Karp et al. 2010).  
2.7.7 Non-pharmacological modalities 
As knowledge regarding drug-related adverse effects is increasing, non-
pharmacological modalities have gained support in the management of pain in older 
adults (Park and Hughes 2012). According to the AGS Beers Criteria, non-
pharmacological modalities should form the base for chronic pain management in 
older adults (AGS 2009). IASP encourages the use of a multidisciplinary approach 
in chronic pain management (IASP 2018). 
Non-pharmacological methods include, for example, exercise, cognitive and 
behavioral techniques (e.g. problem solving, distraction, goal setting), acupuncture, 
mindfulness, massage and osteopathic manual therapies, as well as movement-based 
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approaches and physical therapy (Makris et al. 2014, Wehling 2014, Tick et al. 2018). 
The importance of socialization has also been reported (Kroenke et al. 2013). 
Lifestyle approaches (diet, sleep hygiene) may be beneficial (Tick et al. 2018). 
According to several studies, non-pharmacological methods have proved safe, can 
reduce pain and improve functioning, and should be included in pain management 
whenever possible (Makris et al. 2014, Abdulla et al. 2013, Shekelle et al. 1999). 
In addition to pain reduction, non-pharmacological therapies have the ability to, 
for instance, reduce anxiety and depression, improve sleep, and increase an 
individual’s sense of well-being and recovery motivation (Tick et al. 2018). 
 
2.7.8 Factors associated with the use of analgesics 
In 2010, Pokela and colleagues presented the results of a study in which they 
examined factors associated with daily and as-needed analgesics use in community-
dwelling older adults over 75 years of age in Finland. Therein, female sex, poor self-
rated health, and the use of more than ten non-analgesic drugs were found to 
associate with any analgesic use, and moderate and poor self-rated health were 
associated with opioid use. (Pokela et al. 2010.) Interestingly, while Pokela and 
colleagues (2010) found opioid and daily analgesic use to be inversely associated with 
depressive symptoms, another Finnish study by Gilmartin and colleagues reported 
analgesic use to be independently associated with depressive symptoms in patients 
with Alzheimer’s disease (Gilmartin et al. 2015).  
According to Sarganas and colleagues, adults (18–79 years of age) with low socio-
economic status and who are overweight were found to use significantly more 
prescribed analgesics than adults with high socio-economic status, whereas high 
education and physical activity exceeding 2 hours per week were associated with 
lower use of prescribed analgesics (Sarganas et al. 2015). Additionally, in 2004, a 
relationship was found in a study by Turunen and colleagues between frequent 
analgesics use and high age, low mood, unemployment, and pain (Turunen et al. 
2005).  
Hamina and colleagues studied long-term opioid use in Finnish older adults with 
or without Alzheimer’s disease. Therein, factors associated with chronic opioid use 
included Alzheimer’s disease, female sex, rheumatoid arthritis, low socioeconomic 
status, a history of substance abuse, and chronic benzodiazepine use (Hamina et al. 
2017a). Furthermore, multiple studies outside Finland have investigated factors 
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related to and predicting long-term opioid use in adults of all ages, suggesting high 
baseline opioid dose, the use of transdermal opioids, depression or other psychiatric 
conditions, nicotine dependence, the use of non-opioid analgesics, previous 
benzodiazepine use, patient expectations about using opioids in the future, poor 
overall health, and higher levels of reported distress as predictors (Lalic et al. 2018, 
Quinn et al. 2017, Thielke et al. 2017, Rogers et al. 2013).  
2.7.9 Clinical aspects 
Successful pain management requires the balancing of the benefits and harms of the 
available drugs, as well as lifestyle interventions and the treatment of the underlining 
cause as far as possible (Kalso et al. 2013). 
 Non-pharmacological modalities should always form the basis of chronic 
pain management and should also be given a role in the management of acute pain 
(AGS 2009, Hadjistavropoulos et al. 2007, Makris et al. 2014, Abdulla et al. 2013). 
Previous study findings have indicated that the NSAID prescribing practices do 
not align with the guidelines for safe use in older adults (Gnjidic et al. 2014). The 
mechanisms behind NSAID toxicity are well reported, but the consequences 
frequently remain uncontrolled in clinical practice (Wehling 2014).  
On the other hand, NSAIDs have proved effective in multiple inflammatory and 
chronic pain conditions affecting older adults, such as osteoarthritis, rheumatoid 
arthritis, and gout (Fowler et al. 2014). NSAIDs also improve stiffness and function 
(Golden et al. 2004), which may markedly affect the quality of life.  
Opioids have earned their place as an important part of the treatment of severe 
acute pain and cancer pain (Chou et al. 2009). The selection of the appropriate opioid 
is challenging, and the study results are incongruous. However, one should 
emphasize that the literature consensus supports the individual consideration of the 
opioid selection and dosing according to the patient’s health status, history, 
therapeutic goals, and the predicted adverse effects (Chou et al. 2009). During the 
treatment optimization process, careful surveillance and the assistance of an expert 
team in challenging cases has been recommended (Abdulla et al. 2013, Naples et al. 
2016). Along with their undisputable effect in cancer pain, strong opioids have 
proved useful in different types of surgical procedures and may be used from 
newborns to older patients (Kokki et al. 2012, Panagiotou and Mystakidou 2010). 
Also, it has been presented that a combination of morphine and gabapentin produces 
better analgesia than either independently (Mao et al. 2011), which supports the use 
 51 
of neuropathic drugs as adjuvants even in the absence of an obvious neuropathic 
condition. 
In addition to pain assessment and pharmacological and non-pharmacological 
pain management, monitoring the treatment effectiveness has proved important 
(Hadjistavropoulos et al. 2007). According to an interdisciplinary expert consensus 
statement, the functional status (activities of daily living, mobility, sleep, appetite, 
weight changes, mood, and cognitive impairment) needs to be comprehensively 
assessed (Hadjistavropoulos et al. 2007). Pain management may be considered 
adequate if at least one or more of these domains demonstrates improvement in 
follow-up (AGS 2009). 
In conclusion, importantly, despite the multiple potential adverse effects of all 
generally used analgesics presented above, pain should be treated effectively. The 
importance of individual deliberation and the monitoring of treatment effectiveness 
may thus be highlighted (Haanpaa et al. 2010, Abdulla et al. 2013, Chou et al. 2009). 
2.8 Pain and quality of life 
Several studies have demonstrated the important role of pain and pain coping in 
determining children’s health-related quality of life (Varni et al. 1996b, Schanberg et 
al. 1996). It has been highlighted that assessing only pain intensity is insufficient in 
children (Manworren and Stinson 2016). The impact of pain on children’s quality of 
life (sleep, activities, social, school, etc.) also needs to be carefully assessed using 
specific pain assessment tools (Manworren and Stinson 2016). The combination of 
these should form the basis for planning the pain management (Manworren and 
Stinson 2016). 
Pain intensity and pain coping strategies have been suggested to have an 
independent relationship with multiple domains that comprise the health-related 
quality of life (HRQoL) in children with juvenile idiopathic arthritis (JIA) (Sawyer et 
al. 2004). In 2016, Rabbitts and colleagues reported an association between higher 
widespread pain scores and functional impairment and poorer HRQoL in children 
aged 10–18 years (Rabbitts et al. 2016). Additionally, according to a study by Hunfeld 
and colleagues, the quality of life of 128 adolescents decreased as the intensity and 
frequency of pain increased, but the adolescents’ pain also reduced the quality of life 
of their family members (Hunfeld et al. 2001). 
The effects of pain on the quality of life in adult age groups are evident (Lapane 
et al. 2015, Jensen et al. 2007, Bernfort et al. 2015, Chen et al. 2003, Lacey et al. 
 52 
2014). As the population is aging, the quality of life of the aged population has 
become an increasing interest for citizens, politicians, and researchers alike. Not only 
the etiology of pain but also the impact on the overall quality of life should be 
assessed (Herr and Garand 2001). Notably, it has been presented that pain reduction 
does not always improve the quality of life as expected (Niv and Kreitler 2001). 
However, especially among the oldest old, pain-related functional limitations and a 
frequent need for assistance in daily living have been reported (Jakobsson et al. 
2003). Physical and especially psychological disability as mediators in the relationship 
between the quality of life and pain chronicity in older adults have been underlined 
(Hopman-Rock et al. 1997). According to a study by Jakobsson and colleagues, a 
low quality of life was not solely related to age, but also strongly to being affected by 
pain (Jakobsson et al. 2003). Additionally, Vartiainen and colleagues recently 
suggested that decreased HRQoL in chronic pain mainly originates from the 
psychological aspects and not the intensity of pain (Vartiainen et al. 2016).  
Chronic pain should not be regarded as the expected outcome of aging (Bicket 
and Mao 2015, Thielke et al. 2012). Pain in older adults nearly always results from a 
physical or psychological pathology (Bicket and Mao 2015). Not only medical 
professionals, but older adults themselves require a shift in attitude. Older adults’ 
pain perception has been presented as one major challenge for better pain 
management (Bicket and Mao 2015, Herr and Garand 2001), as pain is often 
considered inevitable with aging and seniors themselves may have drifted towards a 
threshold where they tolerate some pain and consider that to be normal (Gagliese 
and Melzack 1997). On the other hand, a recent meta-analysis has suggested an age-
related increase in the pain threshold, but not in pain tolerance (Lautenbacher et al. 
2017). According to what was presented in the meta-analysis, evidence for an age-
related increase in pain tolerance is stronger than the evidence for a decrease 
(Lautenbacher et al. 2017). Proper pain assessment is the key to understanding the 
effect of pain on a person’s quality of life.  
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2.9 Summary of the Literature 
 
Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage (IASP 2018, IASP 
1994). Pain always includes an emotional component (IASP 2018, Wade et al. 1990), 
and suffering, for example, is always present (Swieboda et al. 2013, IASP 2018). 
Acute pain may be regarded as a symptom of a disease or injury, while chronic pain 
should be seen as a condition in its own right (Bicket and Mao 2015). 
 Pain interference is not always parallel to either pain intensity or tissue 
damage, but it is in a key role in affecting an individual’s quality of life. Children with 
persistent pain are severely impaired in their daily activities, such as attending school, 
and may suffer from severe emotional distress (Coffelt et al. 2013, Zernikow et al. 
2012). Moreover, pain-related sleep disturbances, absences from school, and 
restricted social activities have been reported (Haraldstad et al. 2011). In older adults, 
chronic pain has been considered one of the leading conditions in terms of 
commonness and economic burden (Bicket and Mao 2015). Chronic pain negatively 
interferes with physical functioning and participation in everyday life activities in 
older adults (Ehde and Hanley 2006). 
 Especially chronic pain constitutes a stressor to an individual and may 
disturb his or her psychological balance (Andruszkiewicz et al. 2017). Pain coping 
refers to purposeful cognitive and behavioral efforts to overrule the negative impacts 
of stress (Lazarus 1993). Non-adaptive strategies (e.g. passive avoidance of a stressor, 
catastrophizing) have been suggested to associate with increased pain in children 
(Kaminsky et al. 2006). However, more negative thoughts about the consequences 
of pain, concerns and emotional pain-related representations, lower perceived self-
efficacy, more catastrophizing, and more activity avoidance, as well as an increase in 
pain itself, have been suggested to contribute to declined physical functioning in 
older adults as well (Ilves et al. 2019). The Pain Coping Questionnaire (PCQ) was 
the first – and remains the only – pain coping measurement tool developed 
specifically for children (Reid et al. 1998). After its release, three studies have 
examined the psychometric properties of the PCQ and adequately validated the 
measurement in other languages (Catalan, Danish, Dutch) (Thastum et al. 1999, 
Bandell-Hoekstra et al. 2002, Huguet et al. 2009). 
 The relationship between pain and socioeconomic factors, gender, age, 
disability, psychological and emotional factors, loneliness, sleep disturbances, and 
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lifestyle aspects have been presented in multiple studies in older adults (Ehde and 
Hanley 2006, Crook et al. 1984, Carmaciu et al. 2007, Berkley 1997, Han et al. 2016, 
Vitiello et al. 2009, Heim et al. 2008, Shiri et al. 2010). 
 The overall consensus highlights the under-assessment, under-diagnosis, 
and under-treatment/mistreatment of persistent pain in older people (Gagliese and 
Melzack 1997, Tracy and Sean Morrison 2013, Veal et al. 2014). The treatment 
should focus on pain reduction,  improvements in functioning, and enhanced quality 
of life (AGS 2009, Fine 2012). The role of non-pharmacological pain management 
is emphasized in older adults (AGS 2009, Makris et al. 2014). 
 Pharmacological pain management in older adults comprises multiple 
challenges, and several aspects need to be taken into account when planning the 
treatment (AGS 2009, Abdulla et al. 2013). These include the difficulty of pain 
assessment in older adults with possible cognitive impairment and dementia, 
difficulties in the physical accessibility of treatment, the cost of medication, 
multimorbidity, polypharmacy, age-related alterations in pharmacokinetics and 
pharmacodynamics, and thereby multiple potential adverse effects (AGS 2009, Fine 
2012, McCleane 2007, Nygaard and Jarland 2006, Reynolds et al. 2008). 
The administration of analgesics should follow the principle of “start slow and 
go slow” (AGS 2009). Paracetamol has been considered to be the first-line 
pharmacological therapy, followed by NSAIDs in the absence of contraindications 
(Makris et al. 2014). Opioid administration may be considered with moderate to 
severe cancer and non-cancer pain, but only after precise individual deliberation and 
with careful monitoring (Abdulla et al. 2013, Naples et al. 2016, Huang and Mallet 
2013). Long-term opioid administration for chronic non-cancer pain remains 
controversial (Galicia-Castillo 2016). Neuropathic conditions should be managed 
with neuropathic drugs, and gabapentinoids and especially SNRIs have been 
suggested as being preferred over TCAs (Pickering et al. 2016). 
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3 AIMS OF THE STUDY  
The current study discusses the pain experience in special age groups: in 
children/adolescents and in older adults. The primary aim of the study was to 
develop tools for a better understanding, assessment, and management of pain in 
these age groups. The overall consensus highlights the under-assessment, under-
diagnosis, and under-treatment/mistreatment of pain in both children and older 
people. The Pain Coping Questionnaire provides a unique tool for understanding 
pain coping in children and adolescents and may improve the recognition of 
vulnerable coping at the very early stage of pain becoming chronic. It was 
hypothesized that identifying specific factors related to pain in older adults would 
result in the emergence of groups at risk of persistent pain and enhance preventive 
pain management in the future. Furthermore, improving the knowledge about the 
administration of analgesics among the community-dwelling older adults was 
pursued.  
The main objectives of the study are presented below: 
1. To determine the first- and second-order factor structure and validity of the 
Finnish translation of the Pain Coping Questionnaire for Finnish children and 
adolescents (I) 
2. To examine the self-evaluated pain severity and interference, as well as the factors 
related to pain among community-dwelling older adults (II) 
3. To examine the analgesic purchases of community-dwelling older adults by 
utilizing data from the Social Insurance Institution of Finland (III). 
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4 METHODS  
4.1 Study subjects and data collection 
Studies I–III comprised a total of 1,511 subjects. All data were managed 
anonymously with admission codes. 
Study I: 
The study population (Ntotal = 91) consisted of two samples: JIA patients and 
juvenile patients with chronic non-inflammatory musculoskeletal pain symptoms. 
Out of a total of 97 participants, six were excluded from the analyses due to one or 
more missing value. Therefore, the final analyses were performed with 91 patients 
(65 girls and 26 boys aged 8–15 years, mean age 13.7±2.2 SD). All patients were 
recruited and all measures implemented during routine clinical visits at the hospital. 
The JIA patients were recruited in 2006–2007 at the Rheumatism Foundation 
Hospital in Finland, with a catchment area covering the whole country (Vuorimaa et 
al. 2009). For the patients with JIA, the inclusion criteria were as follows: (1) a JIA 
diagnosis established at least one year prior to the study (Petty et al. 2004) and (2) 
age between eight and fifteen years at the beginning of the study. The current data 
were collected in a follow-up study, which was attended by 64 JIA patients (45% of 
the 142 patients recruited at baseline).  
Patients with non-inflammatory musculoskeletal pain symptoms (N=33) were 
recruited in 2013–2017 at Päijät-Häme Central Hospital, Finland. The inclusion 
criteria were as follows: (1) referral to the central hospital due to musculoskeletal 
pain, (2) age between 13 and 17 years, (3) persistent pain over 3 months, (4) pain not 
explained by a chronic illness, and (5) substantial pain-related disability, including 
poor school attendance and poor sleep (Vuorimaa et al. 2019). The enrolment 
process of study participants in Study I is presented in Figure 1. 
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Figure 1.  Flow chart presenting the inclusion of subjects in Study I. 
 
Studies II and III: 
A total of 2,815 senior citizens (66% of the 4,272 individuals invited) were followed 
in 2002–2012 in a large Good Ageing in Lahti Region (GOAL) cohort study 
(Fogelholm et al. 2006). The GOAL population introduces a stratified (age, sex, 14 
municipalities) random sample of older adults from the Päijät-Häme Region, 
Finland. The region is located in Southern Finland and consists of both rural and 
urban areas, with approximately 220,000 inhabitants. The sample was relatively 
comprehensively representative of the Finnish aged population.  
The studies herein focused on the data from 2012, which was the end point of 
the longitudinal study. The rationale for the cross-sectional focus was that this was 
the only year of the GOAL data collection from which the complete data regarding 
prescribed pain medications were retrievable. Of the 2,815 participants who attended 
at the GOAL baseline in 2002, 1,697 (60%) remained in attendance in 2012. Out of 
these, 277 participants who had not answered both pain questions (SF-36 pain 
intensity and interference) were excluded. Therefore, all statistical analyses were 
executed with 1,420 participants. Hospitalized patients or those in need of 
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institutional care did not participate. Figure 2 presents the flow chart of participants 
in Studies II and III. 
The GOAL study population comprised three age groups (born in 1926–30, 
1936–40, and 1946–50). In 2012, these birth cohorts represented subjects aged 62–
66, 72–76, and 82–86 years. The mean age of all 1,420 participants was 71.2 years 
(SD 7.3). The proportion of women was 55% (784/1,420).  
The GOAL data consisted of a questionnaire as well as clinical and laboratory 
data. All data were collected during four clinical visits in 2002, 2005, 2008, and 2012 
(Fogelholm et al. 2006). Data regarding prescribed pain medications were retrieved 
retrospectively from the Social Insurance Institution of Finland. The Palmenia 
Centre for Continuing Education, Lahti, Finland, was tasked with the collection and 
preservation of the original GOAL data (Fogelholm et al. 2006).  
 
 
 
Figure 2.  Flow chart presenting the inclusion of participants in Studies II and III. 
 
 59 
4.2 Study designs  
Study I 
The translation process of the PCQ was executed by an interdisciplinary team 
comprising an authorized translator, a psychologist, a pediatric rheumatologist, and 
a professional senior researcher. The form was first translated from English into 
Finnish, then back-translated into English by an independent authorized translator 
(who did not participate in the first translation session), and then finally accepted in 
a joint session in which all of the above participated. 
In the PCQ instructions, participants were advised to report how they would act 
when in pain for hours or days on a Likert scale (1: Never–5: Very often). The 
strategies were presented as patterns of behavior by continuing the sentence ‘When 
I am hurt or in pain for a few hours or days, I…’ (e.g. ‘Try to forget it’ or ‘Do 
something I enjoy’).   
The PCQ construct validity was tested using the validated Finnish version of the 
Children’s Depression Inventory (CDI) as a measure of depression or mood 
disturbances (Kovacs 1985, Almqvist 1988), and the Structured Pain Questionnaire 
(SPQ) as a measure of pain frequency (King et al. 1996, Mikkelsson et al. 1998). 
Study II 
Data on the study participants’ SF-36 bodily pain, demographics, life habits, 
morbidity, and symptoms were imbedded in the GOAL questionnaires. In the two-
item SF-36 Bodily Pain questionnaire, participants indicated how severe pain (100 = 
none, 80 = very mild, 60 = mild, 40 = moderate, 20 = severe, 0 = very severe) they 
had experienced during the previous four weeks and how much (100 = not at all, 75 
= a little bit, 50 = moderately, 25 = quite a bit, 0 = extremely) this pain had disrupted 
their everyday work and activity (at home or outside of home) during the previous 
month (Ware and Sherbourne 1992). Bodily pain was calculated as the mean of the 
SF-36 pain intensity and SF-36 pain-related interference scores. The distribution of 
self-reported SF-36 pain intensity (Pain Intensity), SF-36 pain-related interference 
(Pain Interference), and SF-36 bodily pain (Bodily Pain) is presented in Figure 3. 
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Figure 3.  Distribution of self-reported SF-36 pain intensity (Pain Intensity), SF-36 pain-related 
interference (Pain Interference), and SF-36 bodily pain (Bodily Pain) among 1,420 GOAL 
participants. 
 
Based on the self-reports, the participants were divided into four pain groups 
(group I [0–45, moderate to very severe pain intensity and interference], group II 
[47.5–70], group III [77.5–90], group IV [100, no pain intensity and interference at 
all]). The rationale for the four pain groups was to consider separately the subjects 
who had reported high levels of both pain intensity and pain interference (I) and 
those who had reported none (IV). The rest were divided into two groups (II–III) 
to equate the group sizes. 
Factors related to SF-36 bodily pain were examined. The factors considered 
included multiple questionnaire variables, clinical variables, and variables derived 
from a laboratory sample. 
Study III 
The study participants’ pain medication purchases six months prior to and six 
months after the GOAL questionnaire data collection were considered. Data were 
retrieved from the Social Insurance Institution of Finland (KELA). 
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In the first analysis, based on the bodily pain scores, the participants were divided 
into four pain groups (group I [0–45, moderate to very severe pain intensity and 
interference], group II [47.5–70], group III [77.5–90], and group IV [100, no pain 
intensity and interference at all]). The groups were established in order to be able to 
combine pain intensity and pain-related interference and to consider the analgesic 
purchases in relation to these. Analgesic purchases were considered separately for 
three GOAL age groups (62–66, 72–76, and 82–86 years). 
In the second main analysis, participants were divided into two groups (opioid, 
non-opioid) based on whether or not they had purchased opioids. Factors related to 
opioid use were examined.  
In the third analysis, a multivariate analysis was executed to examine factors 
associated with purchases of Level 1 (NSAIDs and paracetamol) and Level 2–3 
analgesics (opioids). 
4.3 Measurements 
4.3.1 The CDI (Study I) 
The Finnish version (validated in a Finnish sample by Almqvist and colleagues in 
1988; Almqvist 1988) consists of 26 of the 27 items included in the English version; 
the question regarding suicide was excluded for ethical reasons (Kovacs 1985). The 
score for each item varies from zero to two. Thus, the total score varies from zero 
to 52. Higher values indicate increasingly severe depression. 
4.3.2 The SPQ (Study I) 
The questionnaire uses a five-level frequency classification of pain over the 
preceding 3 months (seldom or never, once a month, once a week, more than once 
a week, almost daily). Each of the seven pain areas (neck, upper and lower 
extremities, chest, upper back, lower back and buttocks) was scored from zero to 
five, the total score (frequency and area combined) ranging from zero to 28. The 
body area concerned was marked on a picture beside the question to help the child 
to recognize it. 
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4.3.3 The GOAL questionnaire (Studies II–III) 
The GOAL questionnaire used in the current studies consisted of questions 
regarding overall health, lifestyle, attitudes, and the subjective quality of life. All of 
the utilized GOAL variables are presented in Table 4. 
Morbidity constituted diagnoses made by medical professionals (cardiovascular, 
musculoskeletal, psychiatric, pulmonary and neurological diseases, diabetes mellitus 
type II, neoplasms, and fibromyalgia), and self-reported symptoms (joint pain, back 
pain, neck pain, headache, insomnia, depression). Data provided by means of 
laboratory tests (fP-Glucose, fP-Triglyceride, high-density lipoprotein [fP-HDL], 
estimated glomerular filtration rate [eGFR, ml/min/1.73m2], high-sensitivity C-
reactive protein [S-hs-CRP], rheumatoid factor, serum uric acid) as well as clinical 
data (weight, height, blood pressure, waist circumference) were considered. 
Furthermore, the number of doctor’s appointments during the previous 12 months 
was considered.  
Metabolic syndrome was determined as the presence of three or more of the 
following components: 1) waist circumference  102 cm for men and  88 cm for 
women; 2) fP-Triglyceride  1.7 mmol/L or treatment for dyslipidemia; 3) fP-HDL 
1.03 mmol/L for men and  1.29 mmol/L for women, or treatment for 
dyslipidemia; 4) systolic blood pressure  130 mmHg or diastolic blood pressure  
85 mmHg, or antihypertensive medication; 5) fP-Glucose  5.6 mmol/L or the use 
of medication for hyperglycemia (Alberti et al. 2009). 
The household income was determined as follows: taxable household income was 
divided by the square root of the number of people living in the household, indexed 
to the year 2017 (Francoeur 2002). The 3-item Alcohol Use Disorders Identification 
Test-Consumption (AUDIT-C) tool was used to evaluate the weekly doses of 
alcohol consumed (Bush et al. 1998). Leisure Time Physical Activity (LTPA) 
reflected the physical activities, lasting over 30 minutes and making them sweat and 
chuff at least a little bit, that the participants chose to do during their free time (high 
[6–7 times a week], moderate [3–5 times a week], low [1–2 times a week or less, or 
not possible due to injury or illness]) (Yusuf et al. 1996).  
4.3.4 Analgesics 
National register data regarding prescribed pain medication purchased 6 months 
before and after the study visit were retrieved from the Social Insurance Institution 
of Finland (KELA). KELA maintains a nationwide register of all prescriptions and 
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medication purchases. The analgesics considered were level 1 (NSAIDs [M01AE01, 
M01AE51 ibuprofen; M01AE03 ketoprofen; M01AH01, M01AH05, M01AH06 
COX-2 selective inhibitors; M01AC06 meloxicam; M01AE02, M01AE52 naproxen; 
M01AB05 diclofenac; M01AB01 indometin]; N02BE01, N02BE51 paracetamol) 
and level 2–3 analgesics (N02AA01 morphine; N02AA03 hydromorphone; 
N02AA05 oxycodone; N02AA55 oxycodone-naloxone; N02AA59, N02AJ06 
codeine combinations; N02AB03 fentanyl; N02AE01 buprenorphine; N02AX02, 
N02AJ14 tramadol and tramadol combinations), in addition to gabapentinoids 
(N03AX23 gabapentin; N03AX16 pregabalin) and tricyclic antidepressants (TCAs 
[N06AA09, N06CA01 amitriptyline; N06AA10 nortriptyline]). All examined 
analgesics are presented in Table 4. Acetylsalicylic acid was excluded from the 
NSAIDs due to its major use as an antithrombotic drug. 
4.4 Statistical analyses 
Study I: 
SPSS versions 23 and 24 (SPSS, Chicago, IL, USA) were used to execute the 
statistical analyses. The descriptive values of the variables were expressed as means 
and standard deviations and percentages with 95% confidence intervals. Two-sided 
p-values of < 0.05 were considered statistically significant in the analyses. Cronbach’s 
coefficient alpha was used to estimate the reliability. Univariate analyses were applied 
to describe the data. Differences between groups were tested by the independent 
sample t-test.  
Exploratory factor analysis was used to determine the first- and second-order factor 
structure. The principal axis factoring method was used for the first-order analysis 
and the maximum likelihood factoring method for the second-order analysis. 
Promax rotation was used due to the psychometric content of the measured 
questionnaire. Regression analysis was applied to compute the higher-order factor 
scores. The highest factor loading was accepted when lambda was  0.40, and the 
difference in magnitude between loadings on two separate factors needed to exceed 
0.20. The percentage of variance accounted for by each factor was used to determine 
the number of factors included in the rotation. The Kaiser-Meyer-Olkin measure of 
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sampling adequacy and Bartlett’s test of sphericity were employed to evaluate 
whether exploratory factor analysis was appropriate for the present data set.  
 
Table 4.  Variables examined in Studies II and III. World Health Organization Anatomical 
Therapeutic Chemical classification system [ATC]. 
GOAL DATA THE SOCIAL INSURANCE INSTITUTION OF 
FINLAND MEDICATION DATA 
Bodily Pain  NSAIDs 
Sex     M01AE01 ibuprofen 
Age  M01AE51 ibuprofen 
Cohabiting  M01AE03 ketoprofen 
Retirement  M01AH01COX-2-selective inhibitors 
Education years  M01AH05 COX-2-selective inhibitors 
Household income  M01AH06 COX-2 selective inhibitors 
Lifestyle aspects  M01AC06 meloxicam 
 Smoking  M01AE02 naproxen 
 Alcohol consumption  M01AE52 naproxen 
 Leisure-time physical activity     M01AB05 diclofenac 
Clinical data     M01AB01 indometacin 
 Body mass index N02BE01 paracetamol 
 Obesity (body mass index > 30) N02BE51 paracetamol 
 Metabolic syndrome Opioids   
 Waist circumference  N02AA01 morphine 
 Blood pressure   N02AA03 hydromorphone 
Symptoms  N02AA05 oxycodone 
    Joint pain     N02AA55 oxycodone-naloxone 
 Back pain  N02AA59 codeine combinations 
 Neck pain  N02AJ06 codeine combinations 
 Headache  N02AB03 fentanyl 
 Insomnia  N02AE01 buprenorphine 
 Depression  N02AX02 tramadol and tramadol 
combinations 
Morbidity (diagnosed)  N02AJ14 tramadol and tramadol 
combinations 
 Cardiovascular disease Neuropathic drugs 
 Diabetes mellitus type II  N03AX23 gabapentin 
 Musculoskeletal disease  N03AX16 pregabalin 
 Pulmonary disease   N06AA09 amitriptyline 
 Psychiatric disease  N06CA01 amitriptyline 
 Neurological disease  N06AA10 nortriptyline 
 Neoplasm  
 Fibromyalgia  
Laboratory tests  
 Glucose, mMol/L  
 Triglyceride, mMol/L  
 HDL, mMol/L  
 eGFR, mL/min/1.73 cm2  
 hsCRP, mg/L  
 Uric acid, uMol/L  
 RF positive, n (%)  
Visited physician over three times  
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To test construct validity, bivariate correlations were calculated to analyze the 
relationship between PCQ scales and the CDI. To test criterion validity, bivariate 
correlations were calculated to analyze the relationship between PCQ scales and pain 
frequency.  
Study II 
All statistical analyses were carried out with Stata version 15.1 (StataCorp, College 
Station, TX, USA).  
Statistical significances for the hypothesis of linearity across categories of SF-36 
bodily pain were evaluated by using the Cochran-Armitage test for trend and analysis 
of variance with an appropriate contrast. In the case of a violation of the statistical 
assumptions (e.g. non-normality), a bootstrap-type method was used (10,000 
replications). The normality of variables was evaluated by the Shapiro-Wilk W-test.  
Study III 
The Stata version 15.1 (StataCorp LP, College Station, TX, USA) statistical package 
was used for the analyses. 
The descriptive statistics included means and SDs for continuous variables and 
numbers and percentages for categorical variables. Statistical comparisons between 
the groups were performed by the t-test, Chi-squared test, or the Fisher-Freeman-
Halton test when appropriate. In the case of a violation of the assumptions (non-
normality), a bootstrap-type test was used. Multivariate logistic regression was 
applied to investigate factors related to opioid use. As predictors, the following were 
included: pain levels and LTPA (as ordinal variables); sex, MetS, and smoking (as 
dicotomous variables); and age, education years, Audit-C, and number of morbidities 
(as continuous variables). The Hosmer-Lemeshow goodness-of-fit statistics were 
used for the assessment of the final models. The normality of the variables was 
evaluated with the Shapiro-Wilk W test.   
4.5 Ethical aspects 
The principles of the Declaration of Helsinki (World Medical Association 
Declaration of Helsinki. Ethical Principles for Medical Research involving Human 
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Subjects) were followed. The approval for the study was granted by the Regional 
Ethics Committee of Tampere University Hospital. All participants—and in 
connection with those under 15 years of age, also their parents—gave their written 
informed consent prior to data collection.  
There were no conflicts of interest. 
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5 RESULTS 
5.1 The PCQ (Study I) 
5.1.1 Descriptive data   
The mean CDI score was 6.1 ± 6.4 (SD, [CDI: range for each item 0–2, total score 
0–52]). The mean SPQ score was 6.3 ± 6.5 (SD, [SPQ: range for each pain area 0–
7, total {frequency and area combined} score 0–28]). The level of depressive 
symptoms in girls was higher than in boys (6.7 ± 7.0 [SD] vs. 4.5 ± 4.2 [SD], 
respectively). Girls also had higher pain frequency levels (6.8 ± 0.8 [SD] vs. 5.0 ± 6.0 
[SD]). 
5.1.2 First-order factor structure 
Several steps preceded the final first-order factor structure. First, an eight-factor 
structure with all 39 original items was tested using the principal axis factoring 
method with promax rotation. However, in this set, only one item (item 27: Talk to 
a family member about how I feel) loaded primarily onto the eighth factor, and this 
structure was rejected as inadequate. Principally, as determined prior to the analyses, 
the highest factor loading was accepted when lambda was  0.40, and the difference 
in magnitude between loadings on two separate factors needed to exceed 0.20. 
Secondly, the forced seven-factor model was tested, but it was rejected due to 
inadequacy (see determinants of adequacy above). Several other potential structures 
were examined but rejected as incongruent. A common denominator for all the 
rejected structures was the incongruous role of item 27 in the analyses. Finally, item 
27 was deleted due to its poor fit in any hypothetic structure examined.  
The satisfactory exploratory first-order eight-factor structure with 38 items was 
accomplished using the principal axis factoring method with promax rotation. One 
item within the Problem Solving scale had a weak loading (lambda = 0.377). 
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However, the referred item still distinctly loaded more highly on PS than on any 
other factor and was, as a result, retained in the analysis.  
Table 5.  Comparison of the first-order factor structures of the Finnish, English (Reid et al. 
1998), and Danish (Thastum et al. 1999) versions of the PCQ. The factor 
abbreviations in boldface equate to what was presented in the original English 
structure (Reid et al. 1998). 
Number Item Marttinen et al.  Reid et al. Thastum et al. 
1 Ask questions about the problem IS IS excluded 
2 Focus on the problem and see how I can solve it PS PS IP*** 
3 Talk to a friend about how I feel SSS SSS SSS 
4 Tell myself, don't worry, everything will be OK PSS PSS PSS 
5 Go and play BD BD BD 
6 Forget the whole thing CD   (IC -0.329) CD CD 
7 Say mean things to people EXT   (-0.403)    EXT EXT 
8 Worry that I will always be in pain IC IC IC 
9 Ask a nurse or a doctor questions SSS   (IS 0.321) IS excluded 
10 Think about what needs to be done to make things better PS PS IP*** 
11 Talk to someone about how I am feeling SSS SSS SSS 
12 Say to myself, be strong PSS PSS PSS   0.39** 
13 Do something fun BD   (IC -0.374) BD BD 
14 Ignore the situation CD CD CD 
15 Argue or fight EXT EXT EXT 
16 Keep thinking about how much it hurts IC IC IC 
17 Find out more information IS IS   (PS 0.45) IP*** 
18 Think of different ways to deal with the problem PS   (SSS 0.305) PS IP*** 
19 Tell someone how I feel SSS SSS SSS 
20 Tell myself it's not so bad PSS PSS PSS 
21 Do something I enjoy BD   (PS 0.470) BD BD 
22 Try to forget it CD   (SSS -0.311) CD CD 
23 Yell to let off steam EXT EXT EXT 
24 Think that nothing helps IC IC IC 
25 Learn more about how my body works IS IS IP*** 
26 Figure out what I can do about it IC PS IP*** 
27 Talk to a family member about how I feel excluded SSS SSS 
28 Say to myself things will be OK PSS PSS PSS 
29 Do something active BD BD BD 
30 Put it out of my mind CD CD CD 
31 Get mad and throw or hit something EXT EXT EXT 
32 Think that the pain will never stop IC IC IC 
33 Try different ways to solve the problem until I find one that works PS PS IP*** 
34 Let my feelings out to a friend SSS SSS SSS 
35 Tell myself I can handle anything that happens PSS PSS PSS 
36 Do something to take my mind off it BD   (CD 0.339) BD 0.40* excluded 
37 Don't think about it CD CD CD 
38 Curse out loud EXT EXT EXT 
39 Worry too much about it IC IC IC 
BD, Behavioral Distraction; CD, Cognitive Distraction; EXT, Externalizing; IC, 
Internalizing/Catastrophizing; IS, Information Seeking; PS, Problem Solving; PSS, Positive Self-
Statements; SSS, Seeking Social Support. Item 27 (‘Talk to a family member how I feel’) was excluded 
due to statistical reasons. All factor loadings exceeding 0.30 are presented.  
*Reid and colleagues only accepted loadings exceeding 0.45.  
** Thastum and colleagues only accepted loadings exceeding 0.45, and the difference in magnitude 
between the highest and second highest loading needed to exceed 0.20.  
*** Thastum and colleagues integrated Information Seeking and Problem Solving into one, generating 
the factor IP = Information Seeking/Problem Solving. 
The communalities of all strategies were considered tolerable. The eight-factor 
model explained 61.4% of the total variance. The factor structure accomplished in 
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comparison to the structures presented by Reid and colleagues and Thastum and 
colleagues is presented in Table 5 (Reid et al. 1998, Thastum et al. 1999).   
5.1.3 Higher-order factor structure 
The higher-order factor structure was examined with an exploratory factor analysis. 
A three-scale structure using maximum likelihood factoring with promax rotation 
emerged as the most coherent. The scales achieved were Approach, Emotion-
Focused Avoidance, and Distraction. The factor scores of these scales were 
computed with the regression method (Landau 2004). Factor scores exceeding 
lambda = 0.4 were accepted. Behavioral Distraction loaded on both Approach and 
Emotion-Focused Avoidance. Only Cognitive Distraction loaded on Distraction. 
Positive Self-Statements also weakly loaded on Distraction, but evidently had a 
higher loading on Approach. Cronbach’s alpha exceeded 0.75 for all first- and 
higher-order scales. The higher-order structure is presented Table 6. 
Table 6.  Higher-order factor loadings among the Finnish PCQ scales. 
First-order scales APP EFA DIS 
PSS 0.675  (0.304) 
IS 0.643   
SSS 0.773   
BD 0.429 -0.411  
PS 0.607   
IC (0.329) 0.577  
EXT  0.513  
CD   0.886 
BD, Behavioral Distraction; CD, Cognitive Distraction; EXT, Externalizing; IC, 
Internalizing/Catastrophizing; IS, Information Seeking; PS, Problem Solving; PSS, Positive Self-
Statements; SSS, Seeking Social Support; APP, Approach; EFA, Emotion-Focused Avoidance; DIS, 
Distraction. An exploratory higher-order structure was executed using maximum likelihood extraction 
with promax rotation. Factor loadings exceeding 0.40 were accepted; loadings exceeding 0.30 are 
presented.  
Descriptive statistics regarding the higher-order factor scores for children aged 9–12 
years and adolescents aged 13–18 years, for girls and boys, and for JIA patients and 
patients with non-inflammatory musculoskeletal symptoms only showed a 
significant difference in JIA vs. non-inflammatory musculoskeletal symptoms for 
Emotion-Focused Avoidance (JIA 1.9 ± 0.5 [SD] vs. other 2.3 ± 0.7 [SD], p= 0.011). 
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5.1.4 Validity analyses 
Coping strategies were expected to be related to higher CDI and SPQ scores. A 
higher CDI score was positively related to EFA (r = 0.511, p < 0.001) and negatively 
related to DIS (r = -0.234, p = 0.027). A higher SPQ score was positively related to 
EFA (r = 0.433, p < 0.001) and to APP (r = 0.261, p = 0.013). 
5.2 Pain prevalence in older adults (Study II) 
Seventy-eight percent of the participants had experienced pain (SF-36 bodily pain < 
100). The prevalence of a moderate to very severe pain intensity in everyday work 
and activity during the previous month was 24% (SF-36 pain intensity 0–40) and of 
moderate to very severe pain-related interference 20% (SF-36 pain interference 0–
50). 
5.2.1 Pain-related factors in older adults (Study II) 
There was a clear association between a decreasing prevalence of cohabiting as well 
as lower education and increasing experienced SF-36 bodily pain. Additionally, the 
mean household income was inversely proportional to pain, being lowest in group I 
(1,610 euros/month [SD 0.89], p < 0.001). The demographics and socioeconomic 
factors in relation to SF-36 bodily pain are presented in Table 7.  
The prevalence of obesity increased linearly with pain in terms of mean BMI, 
BMI over 30, and waist circumference in both male and female participants. The 
mean BMI was 2.5 units (kg/m2) higher in group I than in group IV (p < 0.001). In 
group I, 40% had a BMI of over 30, compared to the corresponding 20% in group 
IV. The difference in mean waist circumference between subjects in group I and 
those in group IV was 8 cm for females (p < 0.001) and 5 cm for males (p = 0.002), 
indicating more pain among the obese.  
The proportion of low LTPA was highest and that of high LTPA lowest in group 
I. There was no difference in smoking between groups. Alcohol consumption was 
inversely related to experienced pain (AUDIT-C 2.3 [SD 2.1] in group I vs. 2.8 [SD 
2.3] in group IV, p < 0.001). 
Morbidity in terms of diagnoses (cardiovascular diseases, diabetes mellitus type 
II, musculoskeletal diseases, pulmonary diseases, neurological diseases, neoplasms 
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and fibromyalgia) and self-reported symptoms (joint pain, back pain, neck pain, 
headache, insomnia, depressive symptoms) was reported to be highest in participants 
with the most pain, frequency linearly decreasing with decreasing pain. No difference 
in blood pressure was found.  
 
Table 7.  Demographics and socioeconomic factors according to four SF-36 bodily pain levels 
(groups I–IV) among 1,420 GOAL subjects. 
 SF-36 Bodily pain 
I  
(0-45) 
N=244 
II  
(47.5-70) 
N=382 
III  
(77.5-90) 
N=478 
IV  
(100) 
N=316 
P-
value 
Female sex, n (%) 157 (64) 226 (59) 245 (51) 156 (49) ** 
Age, mean (SD) 74 (8) 71 (7) 70 (7) 71 (7) ** 
Cohabiting, n (%) 148 (61) 255 (67) 350 (73) 230 (73) ** 
Pension, n (%) 220 (90) 316 (83) 385 (81) 250 (79) ** 
Education years, 
mean (SD) 
9.1 (2.9) 9.7 (3.3) 9.8 (3.2) 10.1 (3.3) ** 
** p < 0.001. Groups I–IV: group I (0–45, moderate to very severe pain intensity and interference), 
group II (47.5–70), group III (77.5–90), group IV (100, no pain intensity and interference at all). 
Regarding data derived from laboratory testing, the plasma triglyceride level was 
highest (mean 1.39, SD 0.76, p =0.028) and the plasma high-density lipoprotein level 
lowest (mean 1.50, SD 0.42, p = 0.006) in group I. The serum hs-CRP was highest 
in group I. The proportion of participants with positive rheumatoid factor was the 
highest in group I. No significant differences were found in serum glucose, eGFR, 
or serum uric acid levels. 
5.3 Analgesic purchases (Study III) 
Eighty-four percent of the participants had purchased some prescribed analgesics. 
Analgesics were most frequently obtained by individuals in group I, the percentage 
decreasing linearly with the groups. The three age groups (62–66 vs. 72–76 vs. 82–
86 years) did not differ significantly from each other in terms of drug distribution or 
purchasing prevalence. 
NSAID administration emerged as substantial. In group I, 91% had purchased 
NSAIDs. In group IV, the percentage was 70%. The overall NSAID purchasing 
percentage was 77%. Paracetamol was in the clear minority, with an overall 
administration percentage of 41% (62% in group I; 27% in group IV). Of all 
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participants, 8% had purchased gabapentinoids, and 4% had purchased tricyclic 
antidepressants.  
Of all participants, 32% had purchased opioids—the corresponding figure in 
group I was 52%, but 23% of those who reported no pain intensity and no pain-
related interference at all (group IV) were also on opioids. Of the participants with 
moderate to very severe SF-36 bodily pain, 10% had purchased strong opioids.  
When comparing subjects who had and had not used opioids, a moderate mean 
difference was found in SF-36 pain intensity (61 [SD 26] in the opioid group vs. 72 
[SD 23] in the non-opioid group) and in pain-related interference (71 [SD 27] vs. 82 
[SD 22], respectively) (p < 0.001).  
Several morbidities were more prevalent in the opioid group. MetS was present 
in 47% of the participants in the opioid group compared to 40% in the non-opioid 
group (p = 0.009). The proportion of those with a BMI of over 30 was higher in the 
opioid group (31% vs. 26%, p = 0.049). Forty-eight percent of the subjects in the 
opioid group had visited a doctor more than 3 times during the previous 12 months, 
as opposed to the 29% in the non-opioid group (p < 0.001). The prevalence of 
purchasing the other examined analgesics was significantly higher in the opioid 
group. Serum hs-CRP and uric acid levels were significantly higher among opioid 
users. The pain scores, demographic factors, and clinical data of participants who 
were and were not on opioids are presented in Table 8. 
There was no difference in socioeconomic factors, age, sex, smoking, alcohol 
consumption, leisure-time physical activity, or the prevalence of insomnia between 
the opioid and non-opioid group. In addition, no differences in blood pressure, 
serum glucose, triglyceride, or HDL levels, nor in eGFR were found.  
Multivariate analyses revealed that only a higher number of morbidities was found 
to independently associate with purchases of Level 1 (NSAIDs and paracetamol;  
ORLevel1 1.30, 95% CI 1.04–1.63, p = 0.020) and Level 2–3 analgesics (opioids; 
ORLevel2-3 1.53, 95% CI 1.30–1.79, p < 0.001). At the time of the questionnaire 
data collection, 16% of the participants in the opioid group reported no SF-36 pain 
intensity at all and 30% no SF-36 pain-related interference at all. In addition to 
morbidities, according to multivariate logistic regression, MetS was the only factor 
to independently associate with opioid administration in these subjects (ORintensity 
1.99, 95% CI 1.10–3.60, p = 0.022; ORinterference 1.60, 95% CI 1.05–2.43, p = 0.029). 
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Table 8.  Pain, demographic factors, and some clinical data of 1,420 GOAL participants who 
had (Yes) and who had not (No) used opioids during the considered one-year time 
interval. Opioids include weak, intermediate, and strong opioids, as well as the 
paracetamol-codeine combination. 
 Opioids purchased  
No 
N=960 
Yes 
N=460 
P-value 
Pain      
 Bodily Pain, mean (SD) 77 (21) 66 (25) <0.001* 
 Intensity, mean (SD) 72 (23) 61 (26) <0.001* 
 Interference, mean (SD) 82 (22) 71 (27) <0.001* 
Demographics    
 Female sex, n (%) 534 (56) 250 (54) 0.65 
 Age, mean (SD) 71 (7) 72 (7) 0.16 
 Cohabiting, n (%) 662 (69) 321 (70) 0.75 
 Education years, mean (SD) 9.8 (3.2) 9.6 (3.1) 0.37 
 OECDsgrta, mean (SD) 1000€ 1.8 (1.1) 1.7 (0.6) 0.40 
Clinical    
 BMIb, mean (SD) 27.8 (4.8) 28.4 (4.7) 0.021* 
 Obese (BMId30), n (%) 241 (26) 139 (31) 0.049* 
 Waist cm, mean (SD)     
  Female 92 (14) 94 (13) 0.057 
  Male 100 (11) 103 (11) 0.002* 
 MetSc, n (%) 385 (40) 218 (47) 0.009* 
Morbidity (diagnosed), n (%)    
 Cardiovascular disease 413 (43) 225 (49) 0.037* 
 Diabetes mellitus type II 101 (11) 56 (12) 0.35 
 Musculoskeletal disease 330 (34) 231 (50) <0.001* 
 Pulmonary disease 69 (7) 55 (12) 0.003* 
 Psychiatric disease 27 (3) 22 (5) 0.057 
 Neurological disease 25 (3) 16 (6) 0.36 
    Neoplasm 47 (5) 44 (10) <0.001* 
Visited physician  3 times, n (%) 282 (29) 223 (48) <0.001* 
*P-values less than 0.05 were considered statistically significant. Data are presented as mean values 
(SD) and as absolute values and percentages. aOECDsgrt, OECD square root–determined household 
income; bBMI, body mass index; cMetS, metabolic syndrome.  
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6 DISCUSSION  
 
To the best of the author’s knowledge, the current study was the first to evaluate the 
validity of the Finnish PCQ adaptation and the fourth PCQ validity study outside 
the English-speaking countries (Reid et al. 1998, Thastum et al. 1999, Bandell-
Hoekstra et al. 2002, Huguet et al. 2009). The Finnish PCQ factor structure emerged 
as satisfactory both culturally and statistically, and the validity analysis supported the 
legitimacy of future national use. 
The current study presented a self-reported SF-36 bodily pain profile of 
community-dwelling older adults in a sample that relatively well represented the 
general Finnish aging population. Socio-economic factors, lifestyle aspects, several 
morbidities, and some clinical measurements were considered as related factors. The 
vast majority of the participants reported to have endured pain in their everyday 
activities. Individuals who reported the most pain possessed several factors that have 
previously been shown to relate to social exclusion and higher morbidity.  
Based on the data retrieved from the Social Insurance Institution of Finland, 
analgesics were commonly purchased. Over three out of four participants had 
obtained prescribed NSAIDs, and one third had purchased opioids. However, the 
drug distribution emerged as surprising, as paracetamol purchases were in a clear 
minority compared to NSAID purchases, and neuropathic drug use emerged as 
minor. Age made no marked difference in drug distribution and purchasing 
prevalence. Only the number of morbidities was independently associated with 
analgesic purchases in all subjects, though metabolic syndrome was also 
independently associated with opioid purchases in subjects with no pain at all. 
6.1 THE PCQ  
First-order structure 
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The 38-item, eight-factor structure emerged as the most coherent. Regarding 
previous PCQ validity research, two studies had arrived at a comparable eight-factor 
solution (Reid et al. 1998, Bandell-Hoekstra et al. 2002). Thastum and colleagues, in 
their Danish adaptation, presented a seven-factor structure (Information Seeking 
and Problem Solving combined), with three of the original 39 items excluded 
(Thastum et al. 1999). In the current analysis, specific constitutional criteria were 
followed in the structural examination. Due to a poor fit to any scale, item 27 was 
excluded. Item 18 loaded on its scale, PS, relatively weakly but was included due to 
its important role as a part of the factor from the clinical perspective. 
Overall, the solution herein was discovered to be relatively analogous to what was 
presented by Reid and colleagues in 1998. The only differences concerned two items: 
9 (‘Ask a doctor or a nurse questions’) and 26 (‘Figure out what I can do about it’). 
In the version by Reid and colleagues, item 9 was included in IS, whereas it loaded 
on SSS in the current study. From the cultural and linguistic perspective, item 9 could 
logically fit into both referred scales. In Finnish culture, for some patients, doctor’s 
or nurse’s appointments may be the only place where they are able to talk about 
difficult issues. In the present study, item 26 loaded on IC, whereas in the study by 
Reid and colleagues, it loaded on PS. In the Finnish wording, item 26 denotes a deep 
concentration on the problem and may thus relate to internalizing the problem. In 
conclusion, PS, IS, and SSS all lacked one of the original items, while IC and SSS 
both gained one compared to what Reid and colleagues presented. (Reid et al. 1998.)  
Higher-order structure  
To date, only Reid and colleagues had been able to achieve an exploratory higher-
order factor structure of the PCQ (Reid et al. 1998). The reliability of the Catalan 
translation was tested in a confirmatory factor analysis comparing the English eight-
factor and the Danish seven-factor structure in both children and adults—the seven-
factor structure proved most coherent in both children and adults, and a higher-
order confirmatory structure was achieved with both tested models in children but 
not in adults (Huguet et al. 2009).  
In the current study, exploratory factor analysis was selected for the investigation 
of the higher-order structure due to comparability with the English solution. The 
three-scale structure achieved demonstrated many similarities to the structure 
presented by Reid and colleagues in their arthritis/headache sample; in the in the 
present study, BD loaded on both APP and EFA, whereas in the English version it 
loaded on DIS (Reid et al., 1998). In the present study, BD was included in APP due 
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to conceptual reasons; in the Finnish translation, the items comprising the BD scale 
suggest activity and problem solving in coping, which are prominent qualities of the 
APP scale. Additionally, regarding translational difficulties, the Finnish wording of 
the items comprising the CD scale do not represent problem solving itself but rather 
activity to put the problem aside. Previously, it has been argued that distraction is 
not simply a subtype of avoidance coping because it involves the active redirecting 
of attention towards an alternative target (Compas et al. 2001). This was a possible 
reason why CD alone constituted the DIS scale. 
Validity analysis  
Considering the descriptive statistics, patients with non-inflammatory 
musculoskeletal symptoms tended to use more EFA strategies than JIA patients, 
which is most probably due to the fact that there were more adolescents in the non-
inflammatory group. It is possible, however, that non-inflammatory pain without an 
acceptable diagnosis may provoke the worry and anxiety that is prominent in EFA. 
In the present study, higher CDI and SPQ scores were positively related to EFA. 
The results supported what has been presented in the previous reports (Reid et al. 
1998, Thastum et al. 1999). Reid and colleagues found a positive correlation between 
EFA and pain intensity as well as pain duration among arthritis patients; EFA and 
depression also correlated in the headache sample (Reid et al., 1998). Additionally, 
Thastum et al. (1999) previously presented positive correlations between IC and pain 
frequency. In children, a lack of understanding and a mental praxis base may lead to 
an outburst of EFA strategies, when there is a need to deal with unwanted physical 
or mental conditions. EFA strategies include, for instance, ruminating, helplessness, 
arguing, and worrying (Varni et al. 1996a). In several studies, EFA strategies, 
especially aspects of catastrophizing, have been found to associate with multiple pain 
outcomes in adolescents (Wicksell et al. 2011, Kashikar-Zuck et al. 2013, Welkom et 
al. 2013, Chatkoff et al. 2015, Edwards et al. 2016). The non-adaptive aspects of 
EFA strategies were underlined in the current study, as an elevated pain frequency 
and depressive symptoms associated with EFA. 
In 2008, Walker and colleagues presented a validation of pain coping profiles that 
aimed to be clinically more useful compared to the traditional classification. They 
identified six coping profiles: Avoidant, Dependent, Self-reliant, Engaged, 
Infrequent, and Inconsistent. Avoidant and Dependent copers had high levels of 
symptoms (e.g. depression) and disability and were characterized by catastrophizing, 
whereas Self-reliant and Engaged copers had higher pain mastery efforts. The 
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authors suggested an individual selection of treatment options, such as a family 
intervention for Dependent copers and psychotropic medication for Avoidant 
copers. (Walker et al. 2008.) The assessment of both the referred profiles and the 
classical classification presented in the current study may be beneficial in clinical 
practice in terms of achieving a more individualized identification of coping style for 
each patient. 
In the present study, a higher CDI score was also strongly negatively correlated 
to DIS. Previous studies have suggested that children’s use of distraction strategies 
would be associated with less distress (Eccleston 1995, Reid et al. 1998, Compas et 
al. 2001). Higher SPQ was positively related to APP, which was unexpected and may 
be due to the fact that the pain level was relatively moderate in the sample. 
6.2 PAIN IN OLDER ADULTS 
Prevalence of pain  
The majority of the participants in the study had endured pain in their everyday 
activities. Despite it being somewhat in line with the literature (Mantyselka et al. 
2004, Rapo-Pylkko et al. 2017, Karttunen et al. 2014, Karjalainen et al. 2018), the 
high prevalence was surprising. The result was notable, considering that the study 
population consisted of community-dwelling older adults who volunteered for the 
study, and not patients. The result highlights the importance of resources and 
education, focusing on the prevention and treatment of pain in the community, as 
well as on the national and international level. 
One fifth of the participants had experienced moderate to severe pain-related 
interference, which is an important finding. Pain-related interference and 
psychological factors have been suggested to be key aspects in the pain-related 
decrease in the quality of life (Vartiainen et al. 2016, Niv and Kreitler 2001). 
According to the present and previous studies, pain should be regarded as a factor 
to which active efforts should be targeted in order to prevent the decrease in the 
quality of life (Niv and Kreitler 2001). In the present study, multiple non-medical 
factors were found to relate to pain. Whether the experienced interference was 
physical rather than psychological and whether the participants (especially those with 
a scarce social network) were able to unburden themselves regarding the pain 
experience are important questions in terms of the quality of life and require further 
investigation. In terms of the unburdening, the role of professionals is highlighted.  
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The significance of a high prevalence of pain to society is undisputable. It is 
known, that chronic pain patients are among the most frequent users of the health 
care system (Becker et al. 1997). It has previously been estimated that fewer than 2% 
of persons experiencing pain were treated by a pain management specialist and that 
several individuals were not being treated at all (Breivik et al. 2006, Karttunen et al. 
2015). The majority of pain patients are treated by other than pain specialists, who 
may lack knowledge and experience in pain management, especially in more complex 
types of pain, such as in neuropathic pain. In addition to the direct harm caused by 
pain in everyday life functions, pain-related interference may also originate from a 
subjective frustration of feeling like the pain is not adequately treated or the person 
in pain is not sufficiently heard. Older adults with pain may also be in substantial 
need of assistance in their everyday activities due to pain, and without system-level 
organizing, the need may relatively easily be ignored. It may be hypothesized that 
primary care does not have enough resources to focus on pain patients. In the 
present study, however, almost half of the participants who had purchased opioids 
had visited a doctor frequently, indicating that these individuals should also have 
been candidates for non-pharmacological interventions and a careful monitoring of 
treatment effectiveness and adverse effects, had these had been available.  
Evaluating pain is not simple (Jensen et al. 1986, Breivik et al. 2008). In the 
current study, pain estimates were based on self-reporting, which has been 
considered the most reliable method of measuring pain (Booker and Haedtke 2016), 
also for older adults with possible cognitive impairments (Booker and Haedtke 2016, 
Hadjistavropoulos et al. 2010). Persons with cognitive impairment are at an increased 
risk of inadequate pain assessment and treatment (Bicket and Mao 2015).  
Pain-related factors 
Socio-economic factors demonstrated marked variety between the pain groups. As 
presented in the Methods section, the participants were divided into four pain groups 
(group I [0–45, moderate to very severe pain intensity and interference], group II 
[47.5–70], group III [77.5–90], and group IV [100, no pain intensity and interference 
at all]) according to SF-36 pain levels. Education years and mean household income 
were the lowest among participants in group I. Pensioners and those living alone—
thus, without regular social contacts—reported the most pain. The results supported 
what has been presented in previous studies (Gonzalez-Chica et al. 2018, Elliott et 
al. 1999, Baker et al. 2017). It is known that a social network has protective effects 
against morbidity and mortality outcomes (Holt-Lunstad et al. 2010) and that 
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loneliness may predict multiple health concerns affecting older adults, such as pain 
(Jaremka et al. 2013). On the other hand, ineffective pain coping may disturb 
individuals’ social relationships and, therefore, lead to loneliness.  
A BMI of over 30 and a large waist circumference in particular were related to 
higher levels of pain in the current study. As hypothesized, musculoskeletal 
symptoms were related to pain. Furthermore, the LTPA reports supported the 
assumption of restricted mobility possibly due to pain. These may also be related to 
obesity.  
The current concern is that an increasingly large proportion of older adults in the 
Western countries will become marginalized. According to the result herein, a fragile 
social network as well as a low socio-economic status and educational level, which 
characterize social exclusion, are more frequent in those with pain. Additionally, 
obesity, which has also been linked to social exclusion (Lewis et al. 2011), was found 
to be related to more pain. Therefore, seniors with a scarce social network or obesity 
are at an increased risk of pain, and preventive methods should be targeted at these 
individuals. From the clinical perspective, the lack of a cohabitant and a low 
educational and economic status are relatively easily assessable objective factors, 
which may serve as warning signs for several health-related concerns. One alternative 
would be to arrange organized group activities and exercise groups for older adults 
in order to increase the sense of community but also to encourage physical activity. 
Analgesic purchases 
Proper assessment should form the basis of adequate pain management (Reid et al. 
2015). This includes defining the quality of the pain (nociceptive, neuropathic). 
The majority of the current participants had purchased prescribed analgesics 
during the considered year. As expected, the prevalence of analgesic purchases was 
the highest in group I. However, analgesics were also purchased by subjects who, at 
the time of the questionnaire data collection, had reported little or no pain. The drug 
distribution and purchasing prevalence did not differ markedly between the three 
age groups (62–66, 72–76, and 82–86 years).  
Three out of four participants had purchased NSAIDs, which comprises a 
remarkable proportion. Markedly smaller prevalences have been found in previous 
Finnish studies (Hamina et al. 2017b, Pitkala et al. 2015, Pitkala et al. 2002), which 
may be partly due to different study settings. In addition, prior studies have usually 
taken into account regularly taken analgesics, whereas the present study also 
considered pro re nata drugs. Remarkably, the majority of those experiencing no 
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pain at all at the time of the questionnaire data collection had purchased NSAIDs 
during the considered year. It is possible that NSAIDs relieved pain rather effectively 
when used frequently, which is why pain was not reported. On the other hand, 
considering the aspect of pain perception, seniors may tolerate some pain and 
consider it normal, thus reporting no pain despite a clinically relevant pain-causing 
condition. Additionally, the amount of NSAIDs administered may actually be even 
higher than what was estimated herein, when the amount obtained over the counter 
is considered (Enthoven et al. 2014). In older adults, however, a strong association 
has been found between increased age and the use of only prescribed analgesics 
(Sarganas et al. 2015). 
Despite the similar suggestion by Hartikainen and colleagues in 2005 (Hartikainen 
et al. 2005), it  was surprising that the purchasing of paracetamol, which has been 
recommended as the gold standard in geriatric pain management (Makris et al. 2014), 
was in a clear minority compared to the prevalence of NSAID purchases. However, 
medical professionals have recently been encouraged to consider whether to not use 
paracetamol for patients with lower back pain and osteoarthritis due to possible 
inefficacy (Machado et al. 2015), which may explain the lower prescribing 
percentage. Additionally, it is most likely that a major part of older adults’ pain is due 
to musculoskeletal diseases, for which NSAIDs are effective (Mason et al. 2004). 
Furthermore, the incremental availability of selective COX-2 inhibitors may have 
increased the use of NSAIDs due to their suggested more favorable gastrointestinal 
profile (Sostres et al. 2010, Jarupongprapa et al. 2013). It is possible that, for this 
reason, clinicians regard selective COX-2 inhibitors as “safe” for older adults, despite 
the evident renal and cardiovascular adverse effects (Shi and Klotz 2008). 
Opioids were prescribed significantly more frequently than neuropathic drugs. 
TCA purchases were found to be minor. Overall, neuropathic drugs were relatively 
underrepresented, although the prevalence of neuropathic pain is known to increase 
with age (Schmader et al. 2010). Referring to the guidelines, duloxetine and 
venlafaxine (which were not included in the present study) are preferred (Pickering 
et al. 2016), but nortriptyline and gabapentinoids may also be considered for 
neuropathic pain conditions in seniors if contraindications are not present (Abdulla 
et al. 2013). It is possible that a fear of anticholinergic adverse effects and the fact 
that TCAs are considered to be antidepressants restricted their use. Furthermore, 
according to the Beers criteria, TCAs and gabapentinoids should be used with 
caution in older adults due to multiple potential adverse effects (syncope, 
anticholinergic effects, etc.)(By the American Geriatrics Society Beers Criteria 
Update Expert, 2019). Additionally, TCA administration needs to be properly 
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scheduled and monitored. However, the lack of experience in neuropathic pain 
management by clinicians probably also partially explained the low prevalence 
compared to other analgesics.  
In their study, Steinman and colleagues investigated alterations in the use of 
analgesics between 1999 and 2010 in the United States and found that opioid 
administration doubled during the decade, whereas other analgesics remained 
relatively stable (Steinman et al. 2015). Pitkälä and colleagues (2015) also noted the 
increase in opioid administration in their follow-up study (Pitkala et al. 2015). In the 
present study, some opioids were purchased by more half of those with the most 
pain, but also by almost one fourth of those with no pain at all at the time of the 
questionnaire data collection. In 2013, Pitkälä and colleagues presented a prevalence 
of regular opioid use of 17% in older adults living in assisted living facilities and of 
23% in older adults living in nursing homes (Pitkala et al. 2015).  
Referring to what was discussed above, older adults’ pain management is often 
the responsibility of general practitioners, who, in addition to having limited time 
and resources, may not have an expert pain management team to refer to. Despite 
multiple potential adverse effects, opioids may be seen as a tempting choice to be 
prescribed. Opioids are at least relatively effective in almost all pain conditions and 
are not absolutely contraindicated for any patient group. However, the increasing 
use of opioids communicates the message that physicians seem to be in urgent need 
of proper and continuing education in pain assessment and management and that a 
pain management consultant or team should be easily available, especially to general 
practitioners. Such a team could most likely be organized relatively easily at least in 
larger health care centers, if this were considered a priority. 
Importantly, the low level of paracetamol purchases may also partially be due to 
the increasing opioid consumption. The majority of the purchased opioids consisted 
of mild opioids, most likely a paracetamol-codeine combination. Especially for older 
adults, clinicians may avoid prescribing both paracetamol and a paracetamol-codeine 
combination for fear of patient-related inadequate dose titration and, moreover, an 
exceeded paracetamol dose limit. It is possible that a NSAID and a paracetamol-
codeine combination has been seen as an easy and effective combination for both 
acute and chronic pain conditions regardless of the quality of the pain. However, 
codeine administration poses multiple challenges in terms of pharmacokinetics and 
adverse effects (Kirchheiner et al. 2007, Heintze and Fuchs 2015), especially in older 
adults. The efficacy of codeine in an individual is not easily predictable, as a lack of 
CYP2D6 activity makes individuals poor codeine metabolizers, while CYP26D 
duplication makes for ultra-fast metabolizers (Kirchheiner et al. 2007).  
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However, importantly, opioids are an effective and adequate treatment option for 
multiple pain conditions, such as cancer pain. Additionally, in the present study, 
opioid purchases, as well as NSAID and paracetamol purchases, were only 
independently associated with a higher number of morbidities in all subjects, which 
may signify that the indication for prescribing analgesics has most likely been 
adequate. It is possible, however, that individuals receiving analgesics may also have 
multiple interfering medical conditions that may somehow be pain-related and the 
lack of structures (especially in primary care) that would support the use of non-
pharmacological treatment modalities may drive physicians to easily selecting 
pharmacological modalities.  
To determine which opioid to choose (when there is an indication for such a 
choice) is far from simple. Patient-related expectations, the risk profile, and the pain-
causing condition need to be carefully assessed and evaluated (Abdulla et al. 2013, 
Chou et al. 2009). Transdermal opioids, especially a buprenorphine patch, have 
recently become relatively frequent among older people. Hamina and colleagues 
found that long-term use of transdermal opioids was more than twice as frequent 
among patients with Alzheimer’s disease than seniors without Alzheimer’s disease 
(Hamina et al. 2017a). However, transdermal opioids have also been shown to be 
the strongest predictor of chronic opioid administration (Lalic et al. 2018). Weak 
opioids may be considered especially for acute pain conditions (Makris et al. 2014, 
Reid et al. 2015), but it has also been suggested that a low-dose strong opioid could 
be a better choice for some individuals in order to achieve the maximum effect in 
relation to adverse effects (van Ojik et al. 2012). All in all, role of opioids in the 
management of chronic non-malignant pain remains controversial (Abdulla et al. 
2013, American Geriatrics Society Panel on the Pharmacological Management of 
Persistent Pain in Older Persons 2009, By the American Geriatrics Society Beers 
Criteria Update Expert 2019). 
Factors related to opioid purchases 
As discussed above, opioid purchasing emerged as substantial.  
As regards morbidities, cardiovascular, musculoskeletal, and pulmonary diseases 
as well as malignancies were more prevalent among individuals who purchased 
opioids. The opioids primarily comprised weak opioids, which may be an easy and 
effective choice for, for instance, osteoarthritis pain. Opioids constitute an important 
part of pharmacological therapy in many acute non-cancer conditions (e.g. 
myocardial infarction, chronic obstructive pulmonary disease related breathlessness, 
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hip fracture) (Trost and Lange 2012, Ekstrom et al. 2015, Lindestrand et al. 2015), 
but many of these conditions do not require opioid administration after the acute in-
hospital phase. Acute conditions should therefore not explain the high prescribing 
rates. The association with internal medicine diseases may be due to multi-morbidity. 
Patients with a lower socio-economic status, alcohol abuse, or a mental health 
disorder have been reported to be less likely to receive opioids in hospitals or have 
them prescribed to them (Calcaterra et al. 2016, Joynt et al. 2013). An elevated use 
of opioid analgesics among smokers has been suggested (Yoon et al. 2015). 
According to the results of the present study, no difference was found in 
socioeconomic factors, age, sex, smoking, alcohol consumption, LTPA, or the 
prevalence of insomnia between the opioid and non-opioid group. Interestingly, 
there was no difference in participants’ glomerular filtration rates or blood pressures 
between groups. NSAIDs are relatively contraindicated in kidney diseases and 
hypertension (Whelton and Hamilton 1991, Frishman 2002, Gooch et al. 2007), and 
gabapentinoids, for instance, accumulate in chronic kidney disease and may cause 
vertigo (Tawfic and Bellingham 2015, By the American Geriatrics Society Beers 
Criteria Update Expert 2019), which could have explained the tendency to prescribe 
opioids instead. 
Multiple studies have demonstrated an association between obesity and MetS, 
and pain (Eslami et al. 2017, Loevinger et al. 2007, Ray et al. 2011). According to 
Ray and colleagues 2011), a bidirectional pathway may explain this association. In 
their thorough community-based study, both BMI and abdominal obesity were 
associated with chronic pain in older adults; it was suggested that chronic pain 
possibly leads to decreased activity and, conversely, metabolic impairment 
predispose to pain. (Ray et al. 2011.) Regarding the current study, especially a BMI 
of  over 30 and a large waist circumference were related to the most pain. 
MetS consists of insulin resistance, dyslipidemia, elevated blood pressure, and 
central obesity (Kaur 2014). Elevated serum uric acid and hs-CRP levels are often 
present (Kaur 2014, Chen et al. 2007). In the current study, only central obesity and 
elevated hs-CRP were found to be related to more pain. However, MetS was 
independently associated with opioid administration in individuals who had used 
opioids but reported no pain intensity and pain-related interference. Additionally, 
the prevalence of MetS and obesity, as well as hs-CRP and serum uric acid levels, 
were significantly higher in participants using opioids than in those who had not 
purchased opioids. The prevalence of MetS has been suggested to be higher among 
alcohol- and opioid-dependent male inpatients compared to the general population 
(Mattoo et al. 2011). 
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Interestingly, on the molecular level, grave obesity has recently been found to 
associate with decreased u-opioid receptor (MOR) availability in the brain (Karlsson 
et al. 2015). It is known that decreased MOR availability leads to diminished opioid 
sensitivity and to opioid tolerance (Al-Hasani and Bruchas 2011). Further studies are 
needed to specify whether the MetS/obesity–opioid use association evolves from 
the molecular level, or whether obesity, for instance, intensifies musculoskeletal 
symptoms, thereby leading to a need for opioids. 
6.3 STRENGTHS AND LIMITATIONS 
Study I 
The small sample size must be addressed as a limitation in Study I. Secondly, the 
cross-sectional setting did not enable the investigation of causality, which would have 
been informative. Thirdly, a confirmatory factor analysis would have been 
statistically preferred in the higher-order analysis (Aroian 2005). However, it was 
appropriate to observe the exploratory method used by Reid and colleagues, in order 
to be able to compare the results achieved herein to what they had presented (Reid 
et al. 1998). Fourthly, the use of other factors related to coping, such as self-efficacy, 
aside from CDI and pain frequency would have strengthened the current results in 
terms of validity. Finally, adding a generic quality of life scale would have clarified 
the meaning of pain coping in children’s and adolescents’ lives.  
Studies II–III 
The major strength—the combination of self-reporting, clinical data, data provided 
by laboratory sampling, and pain medication data—may be highlighted. Regarding 
pain measurements, the SF-36 bodily pain scale has a favorable fit to the population-
based study setting. Furthermore, the sample size was satisfactory. The sample is 
relatively well representative of Finnish community-dwelling older adults. 
A few limitations need to be addressed. The questionnaire structure regarding 
pain severity may have induced some bias as regards the total pain prevalence 
estimates. The alternatives included very mild and mild pain, and it is likely that the 
majority of seniors had experienced some pain during the preceding month. 
However, almost one fifth of all participants had experienced moderate to very 
severe pain. Furthermore, the exact pain location and chronicity, the nature of the 
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pain (neuropathic, nociceptive), the clinical situation related to analgesics 
administration, the exact number and doses of analgesics, and the amount of 
medicines purchased over the counter were not retrievable. Also, there was a lack of 
a temporal association between the pain assessment and the analgesic purchases. It 
is possible that the pain was not yet present at the time of the self-reporting, or, 
conversely, the administered drugs had already relieved the pain, which is why some 
subjects who had purchased analgesics did not report having pain. Additionally, the 
pattern of analgesics prescribing has most likely been for as-needed use, which has 
also been reported to be the most common in previous studies (Reid et al. 2010), but 
this cannot be stated for certain. Pro re nata administration may, to some extent, 
overestimate the purchasing prevalence. On the other hand, the participants only 
represented the overall healthy seniors; those who suffer the most disability and are 
in need of institutional care—who may have used even higher amounts of 
analgesics—did not participate. 
6.4 FUTURE PERSPECTIVES 
Pain coping is a promising mediating factor, but the exact mechanisms of 
improvement in pain treatment require mediation analyses (Baron and Kenny 1986, 
Kazdin and Nock 2003). Understanding the mechanism of change—for example, 
mediation—may bring order to the interventions, help to foster improvement in the 
clients, and enable the identification of the treatment moderators (Kazdin and Nock 
2003). EFA strategies, such as pain reactivity, catastrophizing, and pain impairment 
beliefs, typically function as mediators when pain or disability is the outcome 
(Wicksell et al. 2011, Kashikar-Zuck et al. 2013). 
Despite the promising results herein, further studies are needed to broaden the 
experience with the PCQ’s applicability to larger samples and especially healthy 
children and adolescents. Furthermore, attention should be paid to moderating 
factors (e.g. diagnosis), parental factors, and their relationship to the pain coping 
strategies. Medical professionals treating pediatric pain need to focus on examining 
pain coping in order to identify which coping styles are effective for each individual 
in the long term. Pain intervention studies in the field of acceptance and 
commitment therapy have shown that avoiding negative psychological events and 
sensations may produce short-term relief (Hayes 1999) but, on the other hand, lead 
to a narrow and inflexible function and increased disability (Wicksell et al. 2011, 
Wicksell et al. 2008). 
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In addition to pain severity, pain-related interference was reported to be relatively 
high among older adults. It is important to consider pain intensity and pain-related 
interference separately, as they rarely are analogous. Further research is needed to 
clarify whether the interference was rather physical or psychical. It has been 
suggested, however, that persistent non-cancer pain does not automatically equate 
with suffering in older people (Shega et al. 2013).  
It has been debated whether clinicians are lacking in courage to provide sufficient 
pharmacological treatment for older adults’ pain (Upshur et al. 2006, Lin et al. 2007). 
According to what has been presented herein, analgesics prescribing emerged as 
active. Further studies are needed to specify the amount of analgesics use among the 
community-dwelling older adult population. 
 Despite the active use of analgesics, however, the majority of the participants 
reported endured pain. Non-pharmacological modalities (e.g. physical therapy, 
cognitive behavioral therapy, pain education) and organized social networking 
should be given a prominent role in pain prevention and management along with 
drug prescribing (Kroenke et al. 2013, Shekelle et al. 1999, Makris et al. 2014, Abdulla 
et al. 2013). The majority of older adults experiencing chronic pain are treated by 
primary care physicians. Resources for an active use of non-pharmacological 
modalities may, to some extent, be available in at least larger health-care centers, but 
the problem lies in the lack of structures supporting their efficient use and the lack 
of multidisciplinary teamwork. An organized multidisciplinary team specializing in 
chronic pain management should also be available in primary care. Older adults are 
at an increased risk of drug-related adverse effects, which supports the use of non-
pharmacological modalities. Pharmacological strategies, especially opioids, should be 
applied only if adequately executed non-pharmacological strategies have proved 
ineffective (Abdulla et al. 2013).  
The high pain prevalence should also be noted as a warning sign of a potential 
decrease in the quality of life, but also in a person’s physical and mental state. 
Inadequate pain management may result in decreased activity levels and, thus, a risk 
for frailty and disabilities, but also in weight gain as well as increased comorbidity 
and poorer outcomes. Furthermore, as a secondary adverse effect, it may cause an 
increased financial burden.  
The results herein need to be considered thoroughly by health care providers and 
clinicians in order to recognize the high prevalence of pain and the risks related to 
it. Moreover, specific pain conditions and the quality of pain need to be recognized 
and evaluated, as neuropathic pain, for example, has been demonstrated to be 
strongly associated with pain-related interference (Thakral et al. 2016, Smith and 
 87 
Torrance 2012). Unfortunately, regarding neuropathic pain, SNRIs were not 
included in the present study. Further studies are needed to evaluate the role of 
venlafaxine and duloxetine in the management of pain in older adults. 
A large body of evidence supports proper pain assessment, the active use of non-
pharmacological modalities, and a careful monitoring of pain coping and treatment 
efficacy in special age groups (Abdulla et al. 2013, Kroenke et al. 2013, Shekelle et 
al. 1999, Makris et al. 2014, Herr and Garand 2001, Manworren and Stinson 2016, 
Beltramini et al. 2017, Varni et al. 1996b, Reid et al. 1998). However, all this requires 
resources and expertise. The results of the  present study indicate that broader 
expertise, such as a special pain management team (also in primary care), and better 
consulting practices at clinics could lead to better outcomes. Accordingly, it may be 
suggested that primary care would include pain clinics similar to what is currently 
offerd in specialized health care. The idea would be to recruit and educate pain nurses 
and physical therapists, and possibly also a social worker who, with the assistance of 
a consultant general practitioner, would organize the pain services of the district. 
This should involve close contact with a pain management specialist in specialized 
health care.  
In conclusion, pain is a frequent and evident factor affecting the quality of life in 
special age groups (Varni et al. 1996b, Schanberg et al. 1996, Bernfort et al. 2015, 
Chen et al. 2003, Lacey et al. 2014). Very young or old age, an immature 
developmental state, or impaired cognition must not be regarded as reasons for not 
assessing pain adequately (Herr and Garand 2001, Herr 2011, Booker and Haedtke 
2016, Manworren and Stinson 2016, Beltramini et al. 2017). Incremental resources 
need to be focused on pain prevention and management at clinics. The importance 
of the involvement of a multidisciplinary team with targeted goals concerning the 
affected domains of the quality of life in pain management needs to be highlighted 
(Niv and Kreitler 2001). There is also a need for individualized deliberation regarding 
pain assessment and management in order to reach the optimal goal in pain 
treatment. 
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7 CONCLUSIONS 
According to the presented results, the following conclusions may be drawn: 
 
1. An exploratory first- and higher-order factor analysis the PCQ provided a 
both culturally and statistically satisfactory structure in the Finnish 
translation. The reliability and validity of the PCQ in future national use may 
be encouraged. The results also support the reliability of the PCQ as an 
internationally used measurement. 
2. Regarding older adults, pain was reported to be more severe in terms of 
intensity and interference by subjects who were obese or had morbidities or 
a low socio-economic status. 
3. NSAID and opioid purchases were revealed to be extensive, whereas 
paracetamol and neuropathic analgesics were in the minority. Further 
consideration of NSAID- and opioid-related contraindications is required. 
4. A higher number of morbidities was found to independently associate with 
purchases of NSAIDs, paracetamol, and opioids. Metabolic syndrome and 
morbidities were found to independently associate with opioid 
administration in those who reported no pain at all at the time of the 
questionnaire data collection.   
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Abstract
Objective: The Pain Coping Questionnaire (PCQ), the ﬁrst validated
pain coping measurement developed speciﬁcally for children, has lacked
proper validation in Finnish. The original PCQ by Reid et al. (Pain 1998;
76; 83–96) comprises eight-ﬁrst-order and three higher-order scales. The
aim herein was to determine the factor structure and validity of the
Finnish PCQ translation in Finnish children.
Methods: Exploratory factor analysis was used for the ﬁrst-order and
higher-order classiﬁcation of 91 recruited patients aged 8–15. Cronbach’s
alpha was used for reliability. Relationships between the Children’s
Depression Inventory, patient-reported pain frequency and pain coping
strategies were examined.
Results: Analyses were executed with 38 items; one was excluded. A
structure of eight-ﬁrst-order (Internalizing/Catastrophizing [IC], Positive
Self-Statements [PSS], Information Seeking [IS], Seeking Social Support
[SSS], Cognitive Distraction [CD], Externalizing [EXT], Behavioural
Distraction [BD], Problem Solving [PS]) and three higher-order scales
(Approach [APP], Emotion-Focused Avoidance [EFA], Distraction [DIS])
proved the most consistent. Four ﬁrst-order scales (PSS, CD, EXT, BD)
emerged as identical to the original solution. Internal consistency
reliability coefﬁcients for all individual ﬁrst- and second-order scales
were satisfactory. A higher CDI score was positively related to EFA and
negatively to DIS, and pain frequency positively related to APP and EFA.
Conclusion: The exploratory factor analysis of the PCQ provided a both
culturally and statistically satisfactory structure in the Finnish
translation. This supports the reliability and validity of the PCQ in future
national use and the value of the questionnaire also outside English-
speaking countries.
Signiﬁcance: This study showed both culturally and statistically
satisfactory factor structure of PCQ in the Finnish translation. This result
supports reliability and validity of the PCQ in the national use in the
future. The result shows that the PCQ is a reliable method to be used in
different linguistic and cultural surroundings and, thus, encourages
using it in various countries. The data consist of two patient groups,
adolescents with JIA and musculoskeletal pain. Pain and speciﬁcally
coping with pain are important aspects of clinical work. A valid pain
coping scale may enhance distinguishing vulnerable pain coping style in
children and adolescent before pain becomes chronic.
© 2018 European Pain Federation - EFIC Eur J Pain  (2018) – 1
1. Introduction
Coping signiﬁes purposeful cognitive and behavioural
efforts to overrule the negative impact of stress
(Lazarus, 1993). A growing consensus supports the
signiﬁcance of pain coping in the understanding of
prolonged pain in children (Reid et al., 1998; Thas-
tum et al., 1999; Bandell-Hoekstra et al., 2002; Her-
mann et al., 2007; Claar et al., 2008; Huguet et al.,
2009; Ostlie et al., 2009; Kashikar-Zuck et al., 2013;
Simons et al., 2015; Agoston et al., 2016; Baastrup
et al., 2016; Gaultney et al., 2017). To measure pain
coping is to distinguish the ongoing cognitive, beha-
vioural and emotional processes connected to pain in
children and adolescents with recurrent or chronic
pain. Measurement of pain coping can help test the
mechanisms of treatment studies (Claar et al., 2008;
Kashikar-Zuck et al., 2013; Simons et al., 2015),
while the psychosocial treatments that address coping
typically have pain intensity or adaptive functioning
as primary outcomes. Pain coping often encompasses
adaptive versus nonadaptive (Claar et al., 2008;
Kashikar-Zuck et al., 2013; Simons et al., 2015) and
active versus passive coping (Baastrup et al., 2016;
Boschen et al., 2016; Edwards et al., 2016).
The Pain Coping Questionnaire (PCQ), the ﬁrst
validated pain coping measurement for children, was
developed and validated by Reid et al. (1998). Apart
from Reid and colleagues, three studies have exam-
ined the psychometric properties of the PCQ and
established an adequate validation in other lan-
guages besides English (Danish, Catalan, Dutch)
(Reid et al., 1998; Thastum et al., 1999; Bandell-
Hoekstra et al., 2002; Huguet et al., 2009). In the
original English version of the PCQ, Reid et al.
(1998) included 39 items describing pain coping
strategies, indicating how often children would exe-
cute each strategy. Reid et al. conducted a factor
analysis (data from healthy children and adoles-
cents), and the 39 items were grouped into eight
conceptually derived scales (Information Seeking,
Problem Solving, Seeking Social Support, Positive
Self-Statements, Behavioural Distraction, Cognitive
Distraction, Externalizing, Internalizing/Catastrophiz-
ing). These ﬁrst-order scales were analysed further
in the arthritis/headache sample for which all partic-
ipants were recruited from neurology and rheuma-
tology clinics. Three second-order scales emerged
(Approach, Emotion-Focused Avoidance, Distrac-
tion). In the Danish translation with data
from mostly healthy youth, Thastum and colleagues
excluded three items (1, 9, 36) and, with the
remaining 36 items integrating the original
Information Seeking and Problem Solving scales,
suggested a seven-scale ﬁrst-order factor structure
(Thastum et al., 1999). Bandell-Hoekstra et al.
(2002) presented eight scales in the cross-sectional
Dutch version but were unable to conﬁrm the
higher-order scales. Huguet et al. (2009) studied the
Catalan version in both school children and adults,
comparing the models by Reid et al. and Thastum
et al. (1999). Their conﬁrmatory factor analysis sup-
ported the seven-factor structure that Thastum et al.
had previously suggested (Thastum et al., 1999;
Huguet et al., 2009).
So far, only Reid et al. (1998) have been able to
conﬁrm an exploratory second-order factor structure
of the PCQ. In this study, one primary objective was
to investigate whether a consistent second-order
structure would surface. Regarding the PCQ, a ﬁrst-
order factor analysis provides speciﬁc information
about children’s coping patterns. However, second-
order analysis would give more information about
the hierarchical structure of coping with pain. More-
over, it would yield a more parsimonious and inter-
pretable picture of children’s pain coping for clinical
use.
To date, the PCQ has been the only pain coping
measurement that has been (1) proved to have good
psychometric quality, (2) designed speciﬁcally for
children and adolescents, (3) subjective, (4) exe-
cutable across a wide range of pain conditions and
(5) validated in multiple languages and cultures
(Reid et al., 1998; Hermann et al., 2007; Huguet
et al., 2009). In childhood diseases with frequent
pain episodes, that is in juvenile idiopathic arthritis
(JIA) and juvenile ﬁbromyalgia, it is important to
have tools to distinguish vulnerable pain coping. For
instance, JIA may have episodes of fatigue and phys-
ical disability (Ostlie et al., 2009; Gaultney et al.,
2017), possibly affecting social life such as school
functioning (Agoston et al., 2016). In particular, in
paediatric chronic pain patients, pain coping styles,
for example catastrophizing, are rather consistently
found to be positively related to pain intensity and
pain-related emotional stress (Varni et al., 1996; Ver-
voort et al., 2010; Simons et al., 2015; Edwards
et al., 2016). In pain treatment, besides pain inten-
sity, it is important to distinguish the cognitive–emo-
tional processes related to pain, because these may
be the possible mechanisms of improvement (Wick-
sell et al., 2011).
Since there remains uncertainty regarding the fac-
tor structure of the PCQ, with the second-order
structure in particular, the aim of this study was to
determine the ﬁrst- and second-order factor
2 Eur J Pain  (2018) – © 2018 European Pain Federation - EFIC
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structures of the Finnish translation of the PCQ. A
valid pain coping scale may improve the recognition
of vulnerable coping at the very early stage of pain
becoming chronic. The hypotheses for the validity
analyses are that emotion-focused coping strategies
would be positively associated with depressive symp-
toms and pain frequency, whereas active coping
methods, such as distraction, would be associated
with less pain and less depressive symptoms.
2. Methods
2.1 The PCQ
The original Pain Coping Questionnaire (Reid et al.,
1998) comprises 39 pain coping strategies indicating
children’s behaviour when in pain. In the form’s
instructions, the subjects are advised to report how
they would act when in pain for hours or days on a
Likert scale, a higher value indicating more frequent
behaviour (1: Never – 5: Very often). The strategies
are presented as patterns of behaviour by continuing
the sentence ‘When I am hurt or in pain for a few
hours or days, I. . .’ (e.g. ‘Try to forget it’, ‘Do some-
thing I enjoy’). The PCQ is independent of the cause
of pain and can be used with children as young as 8
years of age.
An interdisciplinary team comprising an autho-
rized translator, a psychologist, a paediatric rheuma-
tologist and a professional senior researcher
translated the original questionnaire from English to
Finnish. The translated version was back-translated
into English by an independent authorized translator
who did not participate in the ﬁrst translation ses-
sion. The ﬁnal Finnish version was created in a joint
session in which all of the above participated, with
access to the original, translated and back-translated
versions of the PCQ scale.
2.2 The CDI and pain
The Finnish version of the Children’s Depression
Inventory (CDI) was used to measure the depres-
sion/mood disturbances of the patients (Kovacs,
1985). The scale has previously been validated in a
Finnish sample (Almqvist, 1988). The Finnish ver-
sion includes 26 of the 27 items of the English ver-
sion: The question about suicide was excluded for
ethical reasons. The score for each item varies from
zero to two, and the total score thus varies from zero
to 52. Higher values indicate increasingly severe
depression. In this study, the internal consistency of
the scale was good (a = 0.85).
Pain was measured by means of the Structured
Pain Questionnaire (King et al., 1996; Mikkelsson
et al., 1998), which has been used previously in pae-
diatric studies (El-Metwally et al., 2004; Vuorimaa
et al., 2011). The questionnaire uses a ﬁve-level fre-
quency classiﬁcation of pain over the preceding
3 months (seldom or never, once a month, once a
week, more than once a week, almost daily). Each
of the seven pain areas (neck, upper and lower
extremities, chest, upper back, lower back and but-
tocks) was scored from zero to ﬁve, the total (fre-
quency and area combined) score ranging from zero
to 28. The body area concerned was marked on a
picture beside the question to help the child to rec-
ognize it. The internal consistency of the scale was
good (a = 0.81).
2.3 Study population
The study population consisted of two samples. For
the patients with juvenile idiopathic arthritis (JIA;
n = 64), the inclusion criteria were (1) a JIA diagno-
sis established at least 1 year prior to the study
(Petty et al., 2004) and (2) aged between eight and
15 years at the beginning of the study. The JIA
patients were recruited at the follow-up of a larger
study in 2006–2007 at the Rheumatism Foundation
Hospital in Finland, with a catchment area covering
the whole country (Vuorimaa et al., 2009). Of the
142 patients recruited during routine clinical visits at
baseline, 64 attended the follow-up study in which
the current data were collected. In addition, 33
patients with chronic noninﬂammatory muscu-
loskeletal pain symptoms were recruited in 2013–
2017 at P€aij€at-H€ame Central Hospital, Finland. A
total of 97 patients were recruited during routine
clinical visits. We excluded all patients with one or
more missing value (n = 6). Therefore, the ﬁnal
analyses were performed with 91 subjects (65 girls,
26 boys). All measures were implemented at the
hospitals.
The principles of the Declaration of Helsinki
(2013) were followed. All patients and their parents
received both oral and written information on
the study and gave their written informed consent.
The study protocol and procedures were accepted by
the Ethical Committee of the P€aij€at-H€ame Hospital
District.
2.4 Statistical analyses
The factor analyses are described in detail in the
Results section. Cronbach’s coefﬁcient alpha was
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used to estimate the reliability. Univariate analyses
were applied to describe the data. Differences
between groups were tested by independent samples
t-test. To test construct validity, the Children’s
Depression Inventory (CDI) score and, to test crite-
rion validity, the patient-reported pain frequency
score were examined in relation to the second-order
factor solution achieved using a zero-order correla-
tion coefﬁcient. According to previous studies, the
coping strategies were expected to be related to
depressive symptoms and pain frequency. Two-sided
p-values of <0.05 were considered statistically signiﬁ-
cant in the analyses. All statistical analyses were exe-
cuted with SPSS versions 23 and 24 (SPSS, Chicago,
IL, USA).
3. Results
3.1 Participants
The mean age of the patients was 13.7  2.2 (SD)
years. The mean of depressive symptoms measured
by CDI was 6.1  6.4 (SD) and the mean of pain
frequency 6.3  6.5 (SD). In CDI, the level of
depressive symptoms in girls [6.7  7.0 (SD)] was
higher than in boys [4.5  4.2 (SD)]. Girls also had
a higher pain frequency level [6.8  0.8 (SD)] than
the boys [5.0  6.0 (SD)]. The descriptive data show
that the patients had an elevated level of depressive
symptoms and pain frequency compared to other
pain studies (El-Metwally et al., 2004; Vuorimaa
et al., 2011); as a group, however, the patients were
not suffering from depression or strong pain symp-
toms.
3.2 First-order factor analysis
Several steps in the ﬁrst-order exploratory factor
analyses preceded the exploratory factor analysis
result above. First, an eight-factor structure with all
39 items was tested. However, in this set, only one
item (item 27) loaded primarily on the eighth factor.
Principally, the highest factor loading was accepted
when k was ≥0.40. Also, the difference in magnitude
between loadings on two separate factors needed to
exceed 0.20. In the case of many items, these criteria
were not met. Several other potential structures
examined supported the incongruous role of item 27
in the analysis.
The ﬁnal exploratory analysis was executed with
38 items, without item 27. Item 27 was excluded
due to its poor ﬁt to any hypothetic structure exam-
ined, as mentioned above. A satisfactory eight-factor
solution was accomplished using the principal axis
factoring method with promax rotation (see
Table 1). The communalities of all strategies were
considered tolerable (the weakest = 0.268). The
Kaiser–Meyer–Olkin measure of sampling adequacy
(0.77) and Bartlett’s test of sphericity (2237.3,
df = 704, p < 0.001) indicated that exploratory factor
analysis is appropriate for this data set (Field, 2009).
The eight-factor model explained 61.4% of the total
variance.
Eliminating item 27 led to a satisfactory eight-fac-
tor solution. One item in the Problem Solving scale
had a weak loading, k = 0.377, but it was still dis-
tinctly higher than on any other factor and the item
was retained in the analysis. Two items loaded on
two factors (k ≥ 0.40; items 7 and 21) but were both
subsumed under the highest loading factor. Cron-
bach’s alpha internal consistency reliability coefﬁ-
cient for each scale was commendable (all exceeding
0.76). All internal consistency reliability coefﬁcients
are presented in Table 2.
To test construct validity, bivariate correlations
were calculated to analyse the relationship between
PCQ ﬁrst-order subscales and CDI (Table 3; Kovacs,
1985; King et al., 1996). CDI showed signiﬁcant
correlation with IC (r = 0.408, p < 0.001), EXT
(r = 0.288, p = 0.006) and BD (r = 0.335,
p = 0.001). To test criterion validity, bivariate corre-
lations were calculated to analyse the relationship
between PCQ ﬁrst-order subscales and pain fre-
quency. There was a signiﬁcant correlation between
IC (r = 0.398, p < 0.001), EXT (r = 0.327, p = 0.002)
and PS (r = 0.257, p = 0.015), and pain frequency
(Table 3).
3.3 Second-order factor analysis
An exploratory analysis of maximum likelihood
higher-order factoring with promax rotation was
used to examine the higher-order structure of the
eight-ﬁrst-order scales. The factor scores of these
scales were computed with the regression method
(Landau and Everitt, 2004). Three higher-
order scales emerged (Approach, Emotion-Focused
Avoidance, Distraction; Table 4). Factor loadings
exceeding k = 0.40 were accepted. Cronbach’s
alpha reliability coefﬁcients were satisfactory
(Table 2). The goodness of ﬁt (variance accounted
51.6%, v2 = 5.42, p-value = 0.609; Edwards et al.,
2016) was tolerable. Behavioural Distraction loaded
on both Approach and Emotion-Focused Avoid-
ance. Only one-ﬁrst-order factor (CD) loaded on
the Distraction higher-order scale. Positive Self-
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Statements also weakly (0.304) loaded on Dis-
traction, but evidently had a higher loading on
Approach.
Table 5 shows the descriptive statistics regarding
second-order factor scores for primary school-aged
children (9–12 years) and lower and upper sec-
ondary school-aged adolescents (13–18 years), for
girls and boys, and for JIA patients and patients with
noninﬂammatory musculoskeletal symptoms. The
only signiﬁcant difference between the scores was
found for Emotion-Focused Avoidance in JIA
patients vs. patients with noninﬂammatory muscu-
loskeletal symptoms (JIA 1.9  0.5 (SD), other
2.3  0.7 (SD), p = 0.011). No other differences
reached statistical signiﬁcance.
3.4 Validity analysis
To measure construct and criterion validity of the
subscales, the scales were correlated with clinical
Table 1 The Finnish PCQ ﬁrst-order factor analysis.
Items
Factors
IC PSS IS SSS CD EXT BD PS
8 Worry that I will always be in pain 0.931
16 Keep thinking about how much it hurts 0.602
24 Think that nothing helps 0.777
26 Figure out what I can do about it 0.436
32 Think that the pain will never stop 0.798
39 Worry too much about it 0.827
4 Tell myself, don’t worry everything will be OK 0.935
12 Say to myself, be strong 0.717
20 Tell myself it’s not so bad 0.703
28 Say to myself things will be OK 0.756
35 Tell myself I can handle anything that happens 0.847
1 Ask questions about the problem 0.637
17 Find out more information 0.872
25 Learn more about how my body works 0.614
3 Talk to a friend about how I feel 0.661
9 Ask a nurse or a doctor questions (0.321) 0.429
11 Talk to someone about how I am feeling 0.723
19 Tell someone how I feel 0.672
34 Let my feelings out to a friend 0.587
6 Forget the whole thing (0.329) 0.629
14 Ignore the situation 0.419
22 Try to forget it (0.311) 0.527
30 Put it out of my mind 0.717
37 Don’t think about it 0.855
7 Say mean things to people (0.403) 0.694
15 Argue or ﬁght 0.723
23 Yell to let off steam 0.362
31 Get mad and throw or hit something 0.776
38 Curse out loud 0.627
5 Go and play 0.605
13 Do something fun (0.374) 0.582
21 Do something I enjoy 0.551 (0.470)
29 Do something active 0.747
36 Do something to take my mind off it (0.339) 0.507
2 Focus on the problem and see how I can solve it 0.450
10 Think about what needs to be done to make things better 0.497
18 Think of different ways to deal with the problem (0.305) 0.377
33 Try different ways to solve the problem until I ﬁnd one that works 0.424
BD, Behavioural Distraction; CD, Cognitive Distraction; EXT, Externalizing; IC, Internalizing/Catastrophizing; IS, Information Seeking; PS, Problem
Solving; PSS, Positive Self-Statements; SSS, Seeking Social Support. Exploratory factor analysis was performed using the principal axis factoring
method and promax rotation. Item 27 (‘Talk to a family member how I feel’) was excluded due to statistical reasons. All factor loadings exceeding
0.30 are presented. N = 91. Eight-factor structure explained 61.35% of the total variance.
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data. According to previous studies, coping strate-
gies were expected to be related to depressive
symptoms and pain frequency. Speciﬁcally, Emo-
tion-Focused Avoidance would be more likely to
be associated with depressive symptoms (Landau
and Everitt, 2004; Field, 2009; Kashikar-Zuck
et al., 2013; Edwards et al., 2016). The correla-
tions between CDI score and patient-reported pain
frequency and the second-order pain coping scales
are presented in Table 3 (Kovacs, 1985; King
et al., 1996). A higher CDI score was positively
related to Emotion-Focused Avoidance (r = 0.511,
p < 0.001) and negatively to Distraction (r = 0.234,
p = 0.027). Pain frequency was positively related to
Emotion-Focused Avoidance (r = 0.433, p < 0.001)
and to Approach (r = 0.261, p = 0.013).
4. Discussion
To the best of our knowledge, this study was the ﬁrst
evaluating the validity of the Finnish PCQ adapta-
tion and fourth outside the English-speaking coun-
tries (Reid et al., 1998; Thastum et al., 1999;
Bandell-Hoekstra et al., 2002; Huguet et al., 2009).
Our exploratory factor analysis supported the struc-
ture of eight-ﬁrst-order and three higher-order
scales. The results demonstrate adequate validity and
reliability. The administration of the Finnish PCQ in
future studies may be justiﬁed.
4.1 First-order factor structure
In the exploratory factor analysis executed with 38
items, an eight-factor ﬁrst-order structure with the
subscales of IC, PSS, IS, SSS, CD, EXT, BD and PS
proved the most coherent. The original validation of
the PCQ by Reid et al. (1998) also presented an
eight-factor ﬁrst-order structure, as did the Dutch
version by Bandell-Hoekstra et al. (2002). The Dan-
ish adaptation with only 36 items supported a
seven-factor structure with a combined seventh sub-
scale of IS/PS (Thastum et al., 1999).
In the present study, item 27 was excluded. As
presented in the results section, speciﬁc criteria were
followed in constituting the ﬁrst- and second-order
scales, and item 27 poorly met these criteria. The
analyses were thus executed with 38 items. Four
scales (PSS, CD, EXT, BD) emerged as identical to
Reid’s and colleagues’ solution (Reid et al., 1998).
Item 18 loaded relatively weakly on PS, but was
included in the factor due to its important role as a
part of the factor in question.
Compared to the original solution by Reid et al.
(1998), the changes in the current result only con-
cerned two items, 26 and 9. In the present study,
item 9 (included in IS is the solution by Reid et al.)
was included in SSS. In the structure by Reid et al.
(1998), item 27 (excluded from our analysis) also
loaded on SSS. In the present study, item 26 loaded
on IC, whereas in Reid’s and colleagues’ study, it
loaded on PS (Reid et al., 1998). Therefore, PS, IS
and SSS all lacked one item, and IC and SSS both
gained one compared to the Reid et al.’s study (Reid
et al., 1998). However, from a statistical, cultural
and linguistic perspective, all of these differences
seemed rational and the items in question ﬁt well
into the scales they primarily loaded on. In the
Table 2 Internal consistency reliability (Cronbach’s alpha) of the eight-
ﬁrst-order and three-second-order scales of the PCQ.
First-order exploratory analysis
Scales Cronbach’s alpha
Internalizing/Catastrophizing 0.892
Positive self-statements 0.895
Information seeking 0.781
Seeking social support 0.867
Cognitive distraction 0.789
Externalizing 0.762
Behavioural distraction 0.793
Problem solving 0.852
Second-order exploratory analysis
Subscales Cronbach’s alpha
Approach 0.911
Emotion-focused avoidance 0.845
Distraction 0.789
Table 3 Zero-order correlations between the Children’s Depression
Inventory (CDI) score, patient-reported pain frequency and pain coping
scales.
Coping scales CDI (n = 89) Pain (n = 89)
Approach 0.029 0.261*
Positive self-statements 0.052 0.132
Information seeking 0.043 0.208
Seeking social support 0.027 0.201
Behavioural distraction 0.335*** 0.050
Problem solving 0.103 0.257*
Emotion-focused avoidance 0.511*** 0.433***
Internalizing/Catastrophizing 0.408*** 0.398***
Externalizing 0.288*** 0.327**
Distraction 0.234* 0.154
Cognitive distraction 0.031 0.037
CDI, Children’s Depression Inventory score (Kovacs, 1985); Pain, struc-
tured pain questionnaire (SPQ) score (King et al., 1996). Due to miss-
ing data NCDI, Pain = 89.
*p < 0.05, **p < 0.01, ***p < 0.001.
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Finnish PCQ translation, item 9 creates a warm and
conversational connotation, thus ﬁtting well into the
SSS factor. In the Finnish wording, item 26, which
was included in IC, denotes a deep concentration on
the problem. It may thus relate to internalizing the
problem. Along with translational difﬁculties, this
divergence may be related to cultural differences.
4.2 Higher-order factor structure
Thastum et al. (1999) only focused on the ﬁrst-order
factor analysis. Bandell-Hoekstra et al. (2002) were
also not able to achieve the second-order structure.
Huguet et al. (2009)tested the questionnaire’s relia-
bility with conﬁrmatory analysis, investigating chil-
dren and adults separately. They compared the
eight-factor structure by Reid et al. (1998) and Ban-
dell-Hoekstra et al. (2002) and the seven-factor
structure by Thastum et al. (1999), suggesting that
the seven-factor structure with Information Seeking
and Problem Solving combined was the most suit-
able for both age groups. They also accomplished
second-order structures with both tested models in
children.
In the current study, exploratory factor analysis
was used to examine the higher-order structure. A
three-factor model was achieved (Table 4). The fac-
tors had several similarities to those Reid et al.
(1998) presented in their arthritis/headache sample.
The only differing ﬁrst-order scale was BD, which in
the present study loaded relatively equally on
Approach and EFA (a negative association), whereas
in the suggestion by Reid et al. it loaded on Distrac-
tion. One possible explanation for this difference is
that, in the Finnish translation, the items forming
BD suggest activity and problem solving in coping,
which is a prominent quality in the Approach scale.
In the present study, CD alone formed the Distrac-
tion scale. In the Finnish CD scale, the items do not
represent problem solving, but rather activity in put-
ting the problem aside. Previously, it has been
argued that distraction is not simply a subtype of
avoidance coping, because it involves actively redi-
recting attention to an alternative target (Compas
et al., 2001). The means and standard deviations
from the PCQ scales (APP, EFA, DIS) in the sample
were primarily comparable with the Reid et al.’s
Table 5 Means and standard deviations (SD) of the Finnish PCQ second-order scales by sex, age and diagnosis group.
Coping scales
Sex
t-testSex
Age groupa
t-testAge
Diagnosis groupb
t-testDiagn
Girls
M (SD)
Boys
M (SD)
9–12 years
M (SD)
13–18 years
M (SD)
JIA
M (SD)
Other
M (SD)
Approach 2.7 (0.6) 2.7 (0.6) 0.325 2.6 (0.5) 2.8 (0.7) 1.264 2.7 (0.6) 2.7 (0.7) 0.233
Emotion-focused avoidance 2.1 (0.7) 1.9 (0.5) 0.139 1.9 (0.5) 2.1 (0.7) 1.847 1.9 (0.5) 2.3 (0.7)* 2.609*
Distraction 3.2 (0.8) 3.3 (0.9) 1.653 3.2 (0.8) 3.3 (0.9) 0.326 3.3 (0.8) 3.2 (1.0) 0.119
NGirls = 65, NBoys = 26, N9–12 = 33, N13–18 = 58, NJIA = 62, NOther = 29.
*p < 0.05.
aAge = primary school (9–12 years) vs. lower and upper secondary school pupils (13–18 years).
bDiagnosis group. JIA = patients with juvenile idiopathic arthritis; Other = patients with chronic noninﬂammatory musculoskeletal pain symptoms.
Table 4 Higher-order factor loadings among the Finnish PCQ scales in comparison with the exploratory higher-order structure of the arthritis/
headache sample by Reid et al. (1998).
Coping subscales
Higher-order factor structure of the Finnish PCQ Higher-order factor structure by Reid et al.
Approach Emotion-focused avoidance Distraction Approach Emotion-focused avoidance Distraction
Positive self-statements 0.675 (0.304) 0.61
Information seeking 0.643 0.89
Seeking social support 0.773 0.54
Behavioural distraction 0.429 0.411 0.65
Problem solving 0.607 0.81
Internalizing/Catastrophizing (0.329) 0.577 0.67
Externalizing 0.513 0.72
Cognitive distraction 0.886 0.89
Exploratory higher-order factor analysis was executed using maximum likelihood extraction with promax rotation. Factor loadings k ≥ 0.40 were
accepted and loadings k ≥ 0.30 are presented. The total variance explained by three higher-order factors was 51.64%.
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study sample of healthy children and adolescents
and the recurrent pain sample (Reid et al., 1998).
However, in the Finnish sample, the level of EFA in
both sexes and age groups was lower than Reid et al.
presented in the studies. Cultural aspects may
explain the difference.
Considering the descriptive statistics, no major dif-
ferences between groups emerged (see Table 5). Sex,
age and diagnosis group (JIA vs. noninﬂammatory
musculoskeletal symptoms) were examined sepa-
rately. Patients with noninﬂammatory musculoskele-
tal symptoms tended to use more EFA strategies
than JIA patients. This result is most probably
related to the fact that there were more adolescents
in the noninﬂammatory group. It might also be pos-
sible that noninﬂammatory pain without a clear and
acceptable diagnosis may provoke worry and anxiety
prominent in EFA.
4.3 Validity analysis
Thastum et al. (1999) previously presented positive
correlations between IC and pain frequency. This
was in concordance with the studies of Reid et al.
(1998), in which a positive correlation was found
between EFA and pain intensity, as well as pain
duration in arthritis patients, and between EFA and
depression in headache patients. The current study
supported these ﬁndings. Both higher pain frequency
and more depressive symptoms were positively
related to EFA. Children may lack the understanding
and means to deal with ongoing unwanted physical
and mental health conditions, which may burst out
as a utilization of EFA strategies, for example rumi-
nating, helplessness, arguing and worrying (Varni
et al., 1996). Emotion-Focused Avoidance, especially
aspects of catastrophizing, has been found in several
studies to associate with multiple pain outcomes in
adolescents (Wicksell et al., 2011; Kashikar-Zuck
et al., 2013; Welkom et al., 2013; Chatkoff et al.,
2015; Edwards et al., 2016). The current study also
underlined the nonadaptive aspect of this scale, as it
was associated with an elevated level of pain fre-
quency and depressive symptoms. Pain frequency
was also associated with the Approach factor. This
result was unexpected and might be due to the fact
that the level of pain was not very high in the sam-
ple. Depressive symptoms and Distraction had a neg-
ative, although not very strong, correlation. This is
in line with previous studies, in which children’s use
of distraction strategies was related to less distress
(Eccleston, 1995; Reid et al., 1998; Compas et al.,
2001).
Pain coping in childhood and adolescence is multi-
dimensional (Edwards et al., 2016). Although pain
coping is a promising mediating factor, the exact
mechanisms of improvement in pain treatment
require mediation analyses (Baron and Kenny, 1986;
Kazdin and Nock, 2003). Understanding the mecha-
nism of change – for example mediation – brings order
to the interventions, helps to foster improvement in
the clients and enables the identiﬁcation of the mod-
erators of treatment (Kazdin and Nock, 2003). Recent
studies (Wicksell et al., 2011; Kashikar-Zuck et al.,
2013) in the ﬁeld of pain rehabilitation have shown
that Emotion-Focused Avoidance types of coping – for
example pain reactivity, catastrophizing and pain
impairment beliefs – typically function as mediators
when pain or disability is the outcome.
4.4 Signiﬁcance of the results
Children and adolescents are known to use various
strategies to deal with prolonged or subacute pain
(Weekes and Savedra, 1988; Sposito et al., 2015;
Nilsson and Willman, 2016). The PCQ was the ﬁrst
measurement developed speciﬁcally for children to
measure pain coping (Reid et al., 1998). Its popular-
ity most likely originates from its reliability and
validity in administration with several pain problems
and in multiple cultures (Reid et al., 1998; Thastum
et al., 1999; Bandell-Hoekstra et al., 2002; Huguet
et al., 2009). It is also relatively short and executable
for very young children (from 8 years of age).
However, linguistic and structural resemblance
should be taken into consideration. On average, the
Finnish culture, behaviour and problem control dif-
fer indisputably from the Danish or American. In the
present study, cultural aspects have been taken into
account in the translation process.
As a limitation of this study, the small sample size
must be addressed. Further research is needed to
broaden the experience with the PCQ’s operability
for larger masses and healthy children and adoles-
cents. Also, the study was cross-sectional in nature,
which does not enable conclusions to be drawn
about the direction or causality of the relationships
between pain coping and clinical data. Furthermore,
second-order analyses were executed using explora-
tory factor analysis instead of the statistically pre-
ferred conﬁrmatory factor analysis (Aroian and
Norris, 2005). However, one of the main purposes of
the present study was to compare the results to
those presented by Reid et al. (1998). Thus, it was
appropriate to follow their study methodically. Addi-
tionally, only CDI score and patient-reported pain
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frequency were investigated in relation to pain cop-
ing strategies in the validity analyses. Using other
coping-related factors, such as self-efﬁcacy, would
have strengthened the current results. Furthermore,
adding a generic quality-of-life scale would have
clariﬁed the meaning of pain coping in children’s
and adolescents’ lives.
Our results, the higher-order factor structure of the
pain coping scale, provide an avenue for future
research. However, attention should also be paid to
moderating factors (e.g. diagnosis) and parental fac-
tors as well as their relationship to the pain coping
strategies presented. An important question is, Which
coping styles are effective in the long term for children
who have pain symptoms? Recent pain intervention
studies in the ﬁeld of acceptance and commitment
therapy (Hayes et al., 1999) have shown that avoiding
negative psychological events and sensations may
produce short-term relief. However, this pattern may
lead to a narrow and inﬂexible function and increased
disability (Wicksell et al., 2008, 2011).
In conclusion, the explorative factor analysis of
the PCQ provided both culturally and statistically
satisfactory structure in the Finnish translation,
which supports the reliability and validity of the
PCQ in future national use. The results show that
the PCQ is a reliable method to be used in different
linguistic and cultural surroundings and, thus,
encourages its use in various countries.
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